



The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003475
Article Type:	Research
Date Submitted by the Author:	26-Jun-2013
Complete List of Authors:	Currie, Olivia; Christchurch School of Medicine and Health Sciences, Public Health and General Practice Mangin, Dee; Christchurch School of Medicine and Health Sciences, Public Health and General Practice Williman, Jonathan; Christchurch School of Medicine and Health Sciences, Public Health and General Practice McKinnon-Gee, Bianca; Pegasus Health (Charitable) Limited, Bridgford, Paul; Pegasus Health (Charitable) Limited,
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Diabetes and endocrinology, Cardiovascular medicine
Keywords:	Audit < CARDIOLOGY, Lipid disorders < DIABETES & ENDOCRINOLOGY, PRIMARY CARE

SCHOLARONE™
Manuscripts

only

MANUSCRIPT

Title Page

Title

The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.

Authors

Olivia Currie, MBChB, DCH¹, Dee Mangin, MBChB, DPH, FRNZCGP¹, Jonathan Williman, PhD, GradDipBiostat¹, Bianca McKinnon-Gee, BA, BSc, BCom², Paul Bridgford, BSc².

1. Department of Public Health and General Practice, University of Otago, P.O. Box 4345, Christchurch 8140. New Zealand.

2. Pegasus Health (Charitable) Ltd. P O Box 741, Christchurch 8140. New Zealand

Corresponding author

Olivia Currie MBChB DCH, Department of Public Health and General Practice, University of Otago, P.O. Box 4345, Christchurch 8140. New Zealand. olivia.currie@otago.ac.nz

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

Funding

1
2
3
4
5 This research received no specific grant from any funding agency in the public, commercial or not-for-
6 profit sectors.
7
8
9

10 11 12 **Prior Presentations**

13
14
15 None
16
17
18
19

20 **Word count**

21
22
23 Abstract 296 Text 2617
24
25
26
27

28 **Number of Tables**

29
30 3
31
32
33
34
35

36 **Number of figures**

37
38 2
39
40
41
42
43

44 **Ethics Application**

45
46 As all data were de-identified by encryption, ethics approval was confirmed as not required by the
47 National Ethics Advisory Committee, New Zealand as stated in the *Ethical Guidelines for Observational*
48 *Studies: Observational Research, Audits and Related Activities, NEAC, December 2006* (Upper South B
49 Regional Ethics Committee, Ethics ref: URB/12/EXP/022).
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We thank the Canterbury Chair of General Practice Trust (Inc.) for the sponsoring the role of the General Practice Research Registrar for this project. We also thank the University of Otago, New Zealand for providing all computing softwares.

Conflict of Interest Statement

None

Prior Publication

None

Data Sharing

Technical appendix, statistical code, and dataset available from the corresponding author at Dryad repository, who will provide a permanent, citable and open access home for the dataset.

Key Words

Statins, diabetes, antihypertensives, metformin, primary care, electronic prescription.

Abbreviations

ACEi = angiotensin converting enzyme inhibitors

ARB = angiotensin II receptor blockers

CCB = calcium channel blockers

Study Groups:

Antihypertensives TB = thiazides and beta-blockers.

1
2
3
4
5 Antihypertensive AAC = angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium
6
7 channel blockers.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objective: Recent studies suggest statins increase the risk of subsequent diabetes with a clear dose response effect. However patients prescribed statins have a higher background risk of diabetes. This national cohort study aims to provide an estimate of the comparative risks for subsequent development of new-onset diabetes in adults prescribed statins, and those with already higher background risk on cardiovascular risk modifying drugs and a control drug.

Design: Longitudinal cohort study

Setting: Use of routinely collected data from a complete national primary care electronic prescription database in New Zealand.

Participants: 32,086 patients aged between 40 and 60 years in 2005 were eligible and assigned to four non-overlapping groups receiving their first prescription for:

1. diclofenac (healthy population) n=7140
2. antihypertensives thought likely to induce diabetes (thiazides and beta-blockers) n=5769
3. antihypertensives thought less likely to induce diabetes (ACEi, ARBs, CCBs) n= 6565
4. statins n= 12 612

Outcome: Numbers of first metformin prescriptions were compared between these groups from 2006 to 2011.

Results: Patients prescribed statins have the highest risk of receiving a subsequent metformin prescription (HR: 3.31; 95% CI: 2.56 to 4.30; P < 0.01), followed by patients prescribed antihypertensives thought less likely to induce diabetes (HR: 2.32; 95% CI: 1.74 to 3.09; P < 0.01) and patients prescribed

1
2
3
4
5 antihypertensives thought more likely to induce diabetes (HR: 1.59; 95% CI: 1.15 to 2.20; P < 0.01) in the
6
7 subsequent 6 years of follow up, when compared to diclofenac.
8
9

10
11 Conclusions: Not all the risk of diabetes associated with statins can be attributed to increased background
12
13 risk. It also suggests different risk levels may be associated with different antihypertensive drug classes.
14
15 This provides important information for future research and for prescribers and patients when considering
16
17 the risks and benefits of different types of cardiovascular risk modifying drugs.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Article focus:

- Estimates the comparative risks for subsequent development of new-onset diabetes in adults prescribed statins, other groups of cardiovascular risk modifying drugs indicating higher background risk and a control drug.

Key messages:

- Patients prescribed statins have the highest risk of receiving a subsequent metformin prescription (HR: 3.31; 95% CI: 2.56 to 4.30; $P < 0.01$) when compared to control drug
- Patients on antihypertensives are also likely to receive their first metformin prescription when prescribed thiazides and beta-blockers (HR: 2.32; 95% CI: 1.74 to 3.09; $P < 0.01$), and ACEi, ARB and CCB (HR: 1.59; 95% CI: 1.15 to 2.20; $P < 0.01$) compared to control drug. However, this risk is not as high as those on statins.

Strengths:

- A national cohort study using electronic prescription database
- First longitudinal study to compare incidence of subsequent diabetes between statins and antihypertensives with a control drug
- First study to measure outcome by proxy of first metformin prescription as indication of significant diabetes development, no longer amendable to lifestyle changes.

Limitations:

- Confounding factors like BMI, family history and socioeconomic status is not controlled for in this electronic database analysis. However, there is no indication that these factors are not unevenly distributed between the different “high risk” study groups.
- There is a small risk of misclassification for prescription of metformin for other conditions such as polycystic ovary syndrome and extreme insulin resistance with acanthosis nigricans, but these are rare and is likely to only account for a small number of prescriptions.

For peer review only

Text

Introduction

Statins are widely used and have established benefits in the prevention of cardiovascular events.¹ However, recent studies suggested statins may also increase the risk of new-onset diabetes²⁻⁸, which in turn increases risk of cardiovascular events. One meta-analysis reported the odds to be 9% (OR: 1.09; 95% Confidence Interval (CI) 1.02 to 1.17)⁵, with other studies showing the association with pravastatin and rosuvastatin use.^{3,4,7,9-11} More recent data indicates the risk of new-onset diabetes with statin use could also be dose dependent, further supporting a causal link.⁶ Nevertheless, statins may still have an overall cardiovascular benefit.⁵

One of the difficulties in assessing the extent of this risk is that the patients with higher cardiovascular risk who are prescribed statins also carry an increased baseline risk of developing diabetes because of similar risk factors.¹²⁻¹⁴ To understand the extent of the contributions of this increased baseline risk and the risk from the drugs themselves, we compared subsequent diabetes development in patients started on a statin with that in patients started on other drugs for cardiovascular risk management (antihypertensives) and with patients at low baseline risk. We used a complete national prescribing dataset¹⁵ to create a population based cohort constructed of these three groups and compared the risk of subsequent development of clinically significant diabetes in each group.

Methods

Study design: Longitudinal cohort study using a national data set of de-identified routinely collected primary care electronic prescriptions of New Zealanders between ages 40 and 60, receiving first prescriptions of drugs studied (Appendix 1) in the year 2005.

Data source: Nationwide prescription data for the purpose of this study were sourced electronically from a complete national prescribing dataset, the New Zealand Health Information Service' (NZHIS) Pharmaceutical Collection.¹⁶ Community prescribing is electronic in primary care in New Zealand making this information accessible via NZHIS. Individual patients are assigned a unique identifier (NHI number) in

1
2
3
4
5 the New Zealand health system and this is attached to their prescriptions, allowing this to be the main
6
7 data key linkage tool. All NHIs were de-identified at the point of data extraction, and automatically
8
9 assigned a unique encrypted code.
10

11 Cohort construction: The cohort construction is illustrated in Figure 1 (Flow chart of cohort formation). The
12
13 cohort included patients aged 40-60 in the year 2005 without prior prescription of excluded drugs and
14
15 metformin (outcome drug) (Appendix 1), and all patients having received a prescription of at least one of
16
17 the drug of interest between 2005 and 2011. These drugs were statins, antihypertensives, diclofenac
18
19 (comparator drug) or metformin (outcome drug). Some antihypertensives are also associated with
20
21 subsequent development of diabetes. Thiazide diuretics (T) and beta-blockers (BB) are most strongly
22
23 associated with an increased risk,^{14,17-19} whereas little association has been made with angiotensin-
24
25 converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB) and calcium channel blockers
26
27 (CCB).^{18,19} Following the literature, those in the antihypertensive drug group were further divided into
28
29 “Antihypertensives TB” for antihypertensives thought likely to increase diabetes risk (T and BB), and
30
31 “Antihypertensives AAC” for antihypertensives thought less likely to do so (ACEi, ARB and CCB). A total of
32
33 195,194 records listed at least one of the drugs in the drug groups under study: Diclofenac,
34
35 Antihypertensives TB, Antihypertensives AAC, and Statin groups. Patients belonging to two study groups
36
37 concurrently in 2005 were then excluded. Data were further examined and cleaned to identify duplicate
38
39 individuals, exclusion drugs and data entry error. This left 32,086 unique individuals to form the 2005
40
41 study cohort with 7140, 5769, 6565 and 12,612 in Diclofenac, Antihypertensives TB, Antihypertensives
42
43 AAC, Statin groups respectively.
44
45
46
47
48
49

50
51 Exclusion: Patients who had a prescription for oral hypoglycaemics, insulin, oral corticosteroids (known to
52
53 increase the risk of diabetes), or any of the study group medications of interest (Appendix 1) prior to 2005.
54
55 The upper age limit was chosen to limit the inclusion of cardiovascular drugs prescribed for treatment of
56
57 other cardiovascular conditions (e.g. heart failure).
58

59
60 Exposure: New Zealand adults who received their first prescription of statins, antihypertensives, or
diclofenac in the calendar year 2005 without prior prescription of exclusion drugs and metformin.

1
2
3
4
5 Primary Outcome Measure: The proportion of patients receiving their first prescription of metformin in
6
7 the calendar years 2006-2011. Metformin is the recommended first line treatment for newly diagnosed
8
9 type 2 diabetes mellitus in New Zealand.²⁰
10

11 Analysis: Patient baseline demographics were summarised using simple descriptive statistics and
12
13 differences between cohorts were assessed using chi-square statistics calculated on OpenEpi online²¹.
14
15 Since these are routinely collected electronic records, loss to follow up cannot be measured directly, and
16
17 will be measured by proxy of medication persistence, death and emigration rate. Persistence with
18
19 medications was determined as having at least one prescription a year, and persons-years were calculated
20
21 based on this data. Death and emigration rate were calculated by direct age standardisation based on
22
23 information available on Statistics New Zealand life-tables to estimate loss to follow up for our cohorts.²²
24
25 Incidence rates and hazard ratios (HR) with 95% confidence intervals (95% CI) were calculated to compare
26
27 the risk of new-onset diabetes between Diclofenac group and the other three cohorts. HR were calculated
28
29 in SPSS 20.0 for Windows (SPSS Inc) using cox proportional hazards regression, and multivariable analysis
30
31 was used to adjust for differences in the demographic structure of the cohorts. All analyses were 2-sided.
32
33
34
35
36
37
38
39

40 **Results:**

41 Patient characteristics: The baseline characteristics of the cohorts are summarised in Table 1 (Cohort
42
43 demographic). The sex of the patients differed by groups with a higher proportion of females (68.8%, $\chi^2(1)$
44
45 = 447.86 , $p < 0.001$) in the Antihypertensives TB group, and of males (66.6%, $\chi^2(1) = 545.35$, $p < 0.001$) in
46
47 the statin group. The age of patients also differed across groups with patients receiving cardiovascular risk
48
49 modifying drugs tending to be older than those in the diclofenac group ($\chi^2(1) = 1016.39$, $p < 0.001$). New
50
51 Zealand European was the major ethnicity in all study groups. There were more Maori in the Diclofenac
52
53 group with only a few in the statin group ($\chi^2(1) = 301.86$, $p < 0.001$). These differences between groups are
54
55 adjusted for in the multivariable analysis.
56
57
58
59

60 Cohort characteristics and follow up: A total of 32,086 unique patients were eligible for analysis from the
recruitment: 7140 for the Diclofenac group, 5769 for Antihypertensives TB group, 6565 for

1
2
3
4
5 Antihypertensives AAC group, and 12,612 for the Statin group (Figure 1). Persistence with index
6
7 medications for each group was 38.4%, 71.3%, 70.9% and 76.1% respectively (Appendix 2). The persistence
8
9 within the control group was expectedly lower as diclofenac is not usually indicated for long term use. Loss
10
11 of follow up due to deaths and emigration is estimated to be less than 2% of those who were not
12
13 persistent with medications, assuming death and emigration rate were similar to the overall New Zealand
14
15 population within similar age groups during the study period.
16
17

18
19 Primary analysis: Primary outcome results indicated that between 2006 and 2011, 710 patients within the
20
21 four groups received their first prescription of metformin. This represents 1.2%, 1.5%, 2.3% and 3.1% of
22
23 those exposed to Diclofenac, Antihypertensives TB, Antihypertensives AAC and Statin groups respectively.
24
25 The incidence rates were 2.5, 2.8, 4.2 and 5.5 cases per 1,000 person years for first prescription of
26
27 metformin (Table 2) accordingly. As known, patients on any cardiovascular risk modifying drugs had a
28
29 higher risk of new-onset diabetes compared to patients receiving diclofenac. In the multivariable analysis,
30
31 patients commenced on statins had the highest risk of receiving a first prescription of metformin in 6 years
32
33 after exposure compared to the Control group (HR: 3.31; 95% CI: 2.56-4.30; P < 0.01). In contrast to
34
35 existing research, patients on
36
37 Antihypertensives AAC group have moderate risk of receiving their first prescription of metformin in 6
38
39 years (HR: 2.32; 95% CI: 1.74-3.09; P < 0.01), and patients in the Antihypertensives TB group had a slightly
40
41 higher risk (HR: 1.59; 95% CI: 1.15-2.20; P < 0.01) (Table 3), when compared to patients on diclofenac. Our
42
43 analysis indicates a duration-response: The HR of developing new-onset diabetes was approximately
44
45 constant over the duration of the study as demonstrated by the plot for the cumulative hazard ratios for
46
47 the first metformin prescription in each study cohort (Figure 2), adjusting for age, sex, and ethnicity.
48
49

50
51 Subgroup analyses: Patient demographics were analysed to assess other characteristics of recipients of
52
53 first metformin prescription (Appendix 3). Cox regression model analysis revealed that females had a lower
54
55 risk than males (HR = 0.85, 95% CI: 0.72-1.00, p = 0.05), and there was no difference in risk between age
56
57 groups within our cohort age range. However, risks were increased with all other ethnicities when
58
59
60

1
2
3
4
5 compared to New Zealand European. Pacific Island and Asian ethnic group had the highest risk at HR 3.57
6
7 (95%CI: 2.63-4.85, P < 0.01) and HR 3.72 (95% CI: 3.00-4.62, P<0.01) respectively.

8
9
10 To assess whether those at risk of developing diabetes were prescribed higher doses of their prescribed
11
12 medications, the drug doses of their first prescribed indexed medications in 2005 among those prescribed
13
14 metformin were assessed. In the Statin group, 96.9% of patients were prescribed 40mg and less of both
15
16 simvastatin and atorvastatin. For patients in the Antihypertensives TB group, 78.8% of patients were on
17
18 beta blockers and 88% of those on thiazides were on 2.5mg of bendrofluzide. This indicates patients
19
20 commenced on metformin were prescribed conservative dosing of cardiovascular risk modifying drugs.

21
22
23 There were 743 patients who swapped study cohorts during the study period. Of these, 220 were from the
24
25 Diclofenac group, 206 from Antihypertensives TB group, 166 from Antihypertensives AAC group and 151
26
27 from Statin group (Appendix 4). Excluding these patients in a per-protocol analysis had little effect on the
28
29 hazard ratios compared to the intention to treat analysis (results of analysis available but not included),
30
31 which could indicate the effect is rare or that the exposure is steady.
32
33
34
35
36

37 Discussion

38
39 Patients receiving a first prescription for statins were at the highest risk of subsequently developing
40
41 clinically significant diabetes, with a risk three times that of those prescribed diclofenac. Patients
42
43 prescribed ACE inhibitors, ARBs or calcium channel blockers were the next highest risk, being twice as
44
45 likely to receive a metformin prescription, while those prescribed thiazides and beta-blockers were only at
46
47 slightly increased risk.
48
49

50
51 The association between new-onset diabetes, as estimated by first metformin prescriptions, and initiation
52
53 of statins found in this study is consistent with recent reports. However, the risk in this population was
54
55 lower (3.1%) than the 9% risk reported in meta-analyses.²³⁻²⁵ More recent publications have identified the
56
57 risks of new-onset diabetes with statin drug use ranging from 2.4% to 8.5%.²³⁻²⁶ In contrast to our study,
58
59 the diagnosis of diabetes in these other studies were identified by indicators such as disease classification
60
recording, or intermediate indicators such as laboratory investigations of HbA1c and fasting serum glucose

1
2
3
4
5 readings. This will draw in milder levels of hyperglycemia where lifestyle changes can still be the first line
6
7 of management and where laboratory threshold determines disease rates. This study is the first to identify
8
9 the incident rate of clinically significant diabetes in patients prescribed statins as indicated by the first
10
11 prescription of metformin in a non-research population. This is an outcome that matters to patients.
12

13
14 Our study is also the first to compare the risks of diabetes development in patients on statins against
15
16 patients on other cardiovascular risk modifying drugs who might also be considered to be 'high risk'.
17

18 Patients initiated on antihypertensive drugs were, like those prescribed statins, at greater risk of
19
20 developing diabetes compared to those on diclofenac. Our findings therefore allow an assessment of the
21
22 comparative risks of new-onset diabetes in patients with already higher risk on different classes of
23
24 antihypertensives. There may be several explanations for the differences seen. Firstly, it may be a true
25
26 association. Secondly, it may be that patients with risk factors for diabetes (such as obesity) are less likely
27
28 to be prescribed treatment with associated increased risk of diabetes.^{14,27} Hence, they are more likely to
29
30 receive prescriptions of ACEi or ARBs for management of hypertension due to a lesser known risk of
31
32 inducing diabetes. We also observed conservative dosing in patients on thiazides and beta-blockers, which
33
34 may attenuate the risk. This study is not able to answer these questions, but raises these for future
35
36 research.
37
38
39

40
41 Since all data collected are electronic records, patient persistence with medication can be grossly assessed.
42
43 There were high rates of persistence with medications within the study groups, in particular to the
44
45 antihypertensives and the statins. Given only a total of 743 patients (2.3% of 2005 cohort) swapped into
46
47 different study groups during the study period, there were relatively clean groups for analyses of risks.
48

49
50 The development of clinically significant diabetes was estimated using a proxy measure, utilising the first
51
52 prescription of metformin. The validity of using routinely collected and electronically stored prescription
53
54 data for diagnosing diabetes has been previously demonstrated.^{15,28} The use of routinely collected data
55
56 also provides access to a complete national population based cohort. We were able to assess this cohort
57
58 longitudinally over a period of 6 years in a representative primary care population rather than a trial
59
60 population with tightly constrained entry criteria.

Limitations

Our study has several limitations. The nature of the electronic datasets available means it is not possible to obtain other factors contributing to cardiovascular and diabetes risks to more precisely define subgroups and allow direct comparison of the cohorts' baseline levels of risk of developing diabetes (e.g. body mass index and family history). These are major uncontrolled confounding and effect modifiers that cannot be accounted for in this study, however there is no indication to suggest that these risk factors would be unevenly distributed between the high risk prescription groups.

There is also the risk of misclassification. Metformin may also be prescribed for management of other conditions such as polycystic ovary syndrome and extreme insulin resistance with acanthosis nigricans, however this is likely to account for only a small proportion of prescriptions.

It is also uncertain as to how frequently these patients are tested for diabetes mellitus in the primary care setting, as the electronic system is not currently linked to laboratory data. The study is also unable to control for the duration of mild hyperglycaemia prior to commencement of metformin.

In this study, we have not distinguished between the various statin doses and formulations.

Conclusions

Patients initiating treatment with any of the index cardiovascular risk modifying drugs have some risk of developing clinically significant new-onset diabetes compared to those prescribed diclofenac. However, patients prescribed statins have the highest risk of new-onset diabetes, strengthening the recent signal from current literature. Patients prescribed ACE inhibitors, angiotensin II receptor blockers and calcium channel blockers were also at moderately increased risk, while patients prescribed thiazides and beta-blockers only appeared to have a mildly increased risk. The effect seen carries an exposure duration-response groups, and is also seen in patients prescribed relatively low doses of these drugs, which is important information for prescribers. This provides additional information on the comparative safety of these drugs in a real world setting in primary care, where the bulk of these prescriptions are likely to be initiated. This is useful information for doctors and patients considering the balance of harms against the

1
2
3
4
5 potential for benefit of both statins and different cardiovascular risk modifying medications in different
6
7 populations.
8
9

10 11 **Further Research**

12
13
14 Whether there is an additive risk of inducing diabetes with combinations of different cardiovascular risk
15
16 modifying drugs is currently unknown, and an important area for research to inform decision making on
17
18 prescribing, given the prevalence of multi-morbidity and likely co-prescription. This is subject to a further
19
20 study. It is also unclear what effect this additional risk of diabetes will have on morbidity and mortality for
21
22 patients. Diabetes, as a diagnosis based on a measurement, is itself a source of morbidity and mortality
23
24 largely only as a risk factor for other disease, predominantly cardiovascular disease.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References


1. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* Jan 31 2013;1.
2. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. *Arch Intern Med.* Jan 23 2012;172(2):144-152.
3. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. *QJM : monthly journal of the Association of Physicians.* Feb 2012;105(2):145-157.
4. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. *QJM : monthly journal of the Association of Physicians.* Feb 2011;104(2):109-124.
5. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. *Curr Opin Lipidol.* Dec 2011;22(6):460-466.
6. Preiss D, Seshasai S, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A Meta-analysis. *JAMA.* 2011;305(4):2556-2564.
7. Sattar N, Preiss D, Murray H, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet.* 2010;375:735-742.
8. Ridker P, Danielson E, Fonseca F, et al. Rosuvostatin to prevent vascular events in men and women with elevated CRP. *N Eng J Med.* 2008;359(21):2195-2207.
9. Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. *Atherosclerosis.* Jun 2009;204(2):483-490.
10. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. *J Am Coll Cardiol.* Mar 23 2010;55(12):1209-1216.
11. Cholesterol Treatment Trialists' collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. *Lancet.* 2005;366:1267-1278.

- 1
2
3
4
5 12. Movahed MR, Sattur S, Hashemzadeh M. Independent association between type 2 diabetes mellitus
6 and hypertension over a period of 10 years in a large inpatient population. *Clin Exp Hypertens*. May
7 2010;32(3):198-201.
8
9
10
11 13. Verdecchia P RG, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance
12 of new diabetes in treated hypertensive subjects. *Hypertension*. 2004;43:963–969.
13
14
15 14. Dagenais GR AP, Bogaty P, Gerstein H, Lonn E, Yi Q, Yusuf S. Increased occurrence of diabetes in people
16 with ischemic cardiovascular disease and general and abdominal obesity. *Can J Cardiol*. 2003;19:1387-
17 1391.
18
19
20
21 15. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales:
22 population based cohort study using the QResearch database. *BMJ*. 2010-05-21 00:05:49 2010;340.
23
24
25
26 16. Ministry of Health. Pharmaceutical Collection. [http://www.health.govt.nz/nz-health-statistics/national-](http://www.health.govt.nz/nz-health-statistics/national-collections-and-surveys/collections/pharmaceutical-collection)
27
28
29
30
31
32
33 17. Smith SM, Gong Y, Turner ST, et al. Blood pressure responses and metabolic effects of
34 hydrochlorothiazide and atenolol. *Am J Hypertens*. Mar 2012;25(3):359-365.
35
36
37 18. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. *J Hypertens*.
38 2006;24:3-10.
39
40
41 19. Aksnes T, Reims H, Kjeldsen S, Mancia G. Antihypertensive Treatment and New Onset Diabetes
42 Mellitus. *Curr Hypertens Rep*. 2005;7:298-303.
43
44
45
46 20. New Zealand Guidelines Group. *New Zealand Primary Care Handbook 2012*. 3rd ed. Wellington: New
47 Zealand Guidelines Group; 2012.
48
49
50
51 21. Dean A, Sullivan K, Soe M. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version
52 2.3.1. www.OpenEpi.com, updated 2011/23/06, accessed 2012/10/23.
53
54
55
56 22. Statistics New Zealand. <http://www.stats.govt.nz/infoshare>.
57
58
59 23. Wang K-L, Liu C-J, Chao T-F, et al. Statins, Risk of Diabetes, and Implications on Outcomes in the
60 General Population. *J Am Coll Cardiol*. 2012;60(14):1231-1238.

- 1
2
3
4
5 24. Rautio N, Jokelainen J, Oksa H, et al. Do statins interfere with lifestyle intervention in the prevention of
6 diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. *BMJ Open*. January 1, 2012
7 2012;2(5).
8
9
10
11 25. Ma T, Tien L, Fang C-L, Liou Y-S, Jong G-P. Statins and New-Onset Diabetes: A Retrospective
12 Longitudinal Cohort Study. *Clin Ther*. 2012;34(9):1977-1983.
13
14
15 26. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among
16 patients treated with statins: population based study. *BMJ*. 2013-05-23 23:31:42 2013;346.
17
18
19 27. Abdullah A, Stoelwinder J, Shortreed S, et al. The duration of obesity and the risk of type 2 diabetes.
20
21
22
23
24
25
26 28. Tu K, Manuel D, Lam K, Kavanagh D, Mitiku TF, Guo H. Diabetics can be identified in an electronic
27 medical record using laboratory tests and prescriptions. *J Clin Epidemiol*. 2011;64(4):431-435.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figures

Figure 1: Flow chart of cohort formation



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2: Hazard Ratio for first prescription of metformin in each year for different study groups



ew only

Tables

Table 1: Cohort Demographic

Characteristics	OVERALL	Diclofenac Group	Anti-hypertensives TB Group	Anti-hypertensives AAC Group	Statins Group
	% (n)	% (n)	% (n)	% (n)	% (n)
Recruited number of patients	100 (32086)	22.25 (7140)	17.98 (5769)	20.46 (6565)	39.31 (12612)
Sex					
<i>Male</i>	52.98 (16999)	49.69 (3548)	31.20 (1800)	49.52 (3251)	66.60 (8400)
<i>Female</i>	47.01 (15083)	50.29 (3591)	68.80 (3969)	50.46 (3313)	33.38 (4210)
<i>Unknown</i>	4	1	0	1	2
Age					
40-44	22.0 (7045)	33.8 (2415)	20.4 (1179)	19.1 (1255)	17.4 (2196)
45-49	22.7 (7289)	26.4 (1886)	22.4 (1295)	22.0 (1445)	21.1 (2663)
50-54	26.1 (8367)	21.1 (1509)	27.4 (1582)	27.3 (1794)	27.6 (3482)
55-59	29.2 (9385)	18.6 (1330)	29.7 (1713)	31.5 (2071)	33.9 (4271)
Ethnicity					
<i>NZ European[†]</i>	69.46 (22287)	61.3 (4377)	76.39 (4407)	69.23 (4545)	71.03 (8958)
<i>Maori</i>	7.05 (2261)	14.26 (1018)	5.91 (341)	7.75 (509)	3.12 (393)
<i>Pacific Island[*]</i>	3.48 (1116)	8.75 (625)	1.87 (108)	2.83 (186)	1.56 (197)
<i>Asian[#]</i>	5.31 (1703)	5.04 (360)	5.23 (302)	4.90 (322)	5.70 (719)
<i>Others[^]</i>	0.93 (298)	1.44 (103)	0.81 (47)	0.70 (46)	0.81 (102)
<i>Unknown[@]</i>	4421	657	564	957	2243

Table 2: Incidence rate for first prescription of metformin

Groups	Person-time	Number of new cases	Incidence rate cases per person year	Incidence rate cases per 1,000 person- years
Diclofenac	33190	84	0.00253	2.5
TB	30791	85	0.00276	2.8
AAC	35383	150	0.00424	4.2
Statin	70455	391	0.00555	5.5

Table 3: 6 year risk of first prescription of metformin in study groups compared to control group

			Univariable Analysis			Multivariable Analysis ^{1,2}		
	Total	Metformin (%)	HR	95% CI	P	HR	95% CI	P
Cohort								
Diclofenac	7140	84 (1.2)	1.00			1.00		
TB	5769	85 (1.5)	1.25	0.93-1.70	0.142	1.59	1.15-2.20	0.005
AAC	6565	150 (2.3)	1.95	1.50-2.55	<0.0001	2.32	1.74-3.09	<0.0001
Statin	12612	391 (3.1)	2.66	2.10-3.37	<0.0001	3.31	2.56-4.30	<0.0001

¹Cox Regression²Adjusting for: Age, sex, and ethnicity.

Appendices

Appendix 1: Summary of study analysis categories and drug lists

Groups	List of drugs	Sub group
Exclusion criteria	Insulin Neutral, Insulin Isophane, Insulin Isophane with Insulin	
Drugs (associated with increased risk of diabetes or are treatment for diabetes)	Neural, Insulin Lispro with Insulin Lispro Protamine, Insulin Glargine, Insulin Aspart, Insulin Glulisine, Insulin lispro, Acarbose, Glibenclamide, Gliclazide, Glipizide, Pioglitazone, Spironolactone, Cyproterone Acetate with Ethinyloestrodil, Cyproterone acetate, Dexamethasone, Fludrocortisone Acetate, Hydrocortisone tablets, Methylprednisone, Prednisone Sodium Phosphate, Prednisone	
Diclofenac group	Diclofenac Sodium enteric coated tablets, Diclofenac Sodium Long Acting Tablets	
Anti-hypertensives TB Group	Atenolol, Carvedilol, Celiprolol, Labetalol, Metoprolol Succinate, Metoprolol Tartrate, Nadolol, Propanolol, Sotalol, Labetalol	BB
	Bendrofluazide, Chlorthalidone, Indapamide, Chlorothiazide	T
Anti-hypertensives AAC Group	Captopril, Cilazapril, Enalapril, Lisinopril, Quinapril	ACEi
	Candersartan, Losartan	ARB
	Amlodipine, Felodipine, Isradipine, Nifedipine, Diltiazem Hydrochloride, Verapamil Hydrochloride	CC
Statin Group	Atorvastatin, Pravastatin, Simvastatin	
Outcome Group	Metformin Hydrochloride	

Appendix 2: Number of patients persistent with medications in each cohort in every study year

Cohort\Years	2006	2007	2008	2009	2010	2011	%
TB	5769	5202	4834	4547	4339	4115	71.3%
AAC	6565	5958	5583	5227	4955	4654	70.9%
STATIN	12612	11752	11186	10757	10187	9593	76.1%

For peer review only

Appendix 3: 6 year risk of first prescription of metformin in different patient demographics.

					Univariable Analyses			Multivariable Analyses ^{1,2}		
	Total	%	Metformin	%	HR	95% CI	P	HR	95% CI	P
Sex										
M	16999	53.0%	409	1.3%	1.00	-	-	1.00	-	-
F	15083	47.0%	301	0.9%	0.83	0.71-0.96	0.01	0.85	0.72-1.00	0.05
Unknown	4	0.00%	0	0.0%	-	-	-	-	-	-
Age										
40-44	7045	22.0%	163	0.5%	1.00	-	-	1.00	-	-
45-49	7289	22.7%	156	0.5%	0.93	0.74-1.15	0.49	0.87	0.69-1.10	0.25
50-54	8367	26.1%	185	0.6%	0.96	0.77-1.18	0.67	0.88	0.70-1.11	0.27
55-59	9385	29.2%	206	0.6%	0.95	0.77-1.17	0.61	0.96	0.77-1.20	0.71
Ethnicity										
European	22287	69.5%	384	1.2%	1.00	-	-	1.00	-	-
Maori	2261	7.0%	66	0.2%	1.70	1.31-2.21	<0.01	2.23	1.71-2.91	<0.01
PI	1116	3.5%	49	0.2%	2.57	1.91-3.47	<0.01	3.57	2.63-4.85	<0.01
Asian	1703	5.3%	106	0.3%	3.69	2.98-4.57	<0.01	3.72	3.00-4.62	<0.01
Other	298	0.9%	11	0.0%	2.17	1.18-3.93	0.01	2.43	1.33-4.43	<0.01
Note:										
*European = NZ European, Other European, European NFD										
*Pacific Island = Cook Island, Fijian, Niuean, Samoan, Tokelauan, Tongan, Pacific Island, Other Pacific Island										
#Asian = Asian, Chinese, Other Asian, Indian, Southeast Asian										
^Others = African, Latin American/Hispanic, Middle Eastern, other, other ethnicity										

¹Cox Regression²Adjusting for: Age, sex, ethnicity, and study cohorts.

Appendix 4: 743 Patients who swapped study groups during study period

Group Swaps (From/To)	No Metformin	Metformin	Total Patient
Diclofenac Group	207	13	220
Antihypertensives TB Group	78	1	79
Antihypertensives AAC Group	56	1	57
Statin Group	73	11	84
Antihypertensives TB Group	198	8	206
Diclofenac Group	82	1	83
Antihypertensives AAC Group	98	6	104
Study Group	18	1	19
Antihypertensives AAC Group	163	3	166
Diclofenac Group	40	1	41
Antihypertensives TB Group	107	1	108
Statin Group	16	1	17
Statin Group	149	2	151
Diclofenac Group	104	1	105
Antihypertensives TB Group	24	0	24
Antihypertensives AAC Group	21	1	22
Total	717	26	743

Research Protocol

Project title: Drug Induced Diabetes: A Case of statins versus antihypertensives.

Date: April 2012

Principal investigator: Dr. Olivia Currie

Supervisor: Assoc. Professor Derelie Mangin

Project summary:

This is an observational prospective cohort study to assess whether the incidence of new onset diabetes is increased with the use of statin drugs; when compared to blood pressure drugs, and to a control group. The importance is indicated from previous experience with unwanted increased rate of cardiovascular events due to new onset diabetes with use of certain antihypertensives (1, 2). We will look at patients with first prescription of statin drugs and assess the proportion of users who develop diabetes in 5 years. We will compare this with groups of patients with first prescription of drugs for high blood pressure (high diabetes risk control group), and patients with none of these prescriptions but who have attendance for an ACC-related condition (normal control group). We will use clinical data held electronically on drug prescriptions and laboratory tests on the Pegasus Health Community ePrescription system.

Background:

In modern cardiovascular risk management, statin drugs are popular and beneficial adjuncts for prevention of primary and secondary cardiovascular events. All forms of pharmacotherapy have side effects. Common to statin drugs are increases in liver transaminases, muscle aches, cognition impairment and rhabdomyolysis, albeit rare. However, there is now new evidence to suggest that statin drugs could have drug class effect in causing diabetes in previously non-diabetic individuals (3).

Statin induced diabetes was first observed in the JUPITER trial (4) with relation to Rosuvostatin use in non-diabetic subjects. It was reported by physicians involved in the trial as a secondary outcome and concluded that more evidence is needed to confirm the observed effect. Following that, multiple meta-analyses correlated an overall 9% increased risk of diabetes with statin use with newer evidence showing association with Pravastatin and Rosuvastatin use (5-8). The meta-analyses, should be interpreted with caution as diabetes is often not the primary outcome in the trials analysed. Recent evidence indicates the risk of new onset diabetes with statin use could also be dose dependent (9). These drugs may still have an overall cardiovascular benefit nonetheless (10).

One of the difficulties in assessing the extent of the risk is that patients of higher cardiovascular risk also carry an increased risk of developing diabetes. In order that the risks and benefits of these drugs to be properly considered by patients and doctors, decisions whether to use them, it is very important to understand the extend of this risk in already high risk patients as development of diabetes further increases cardiovascular risk and carries its own morbidity, reducing lifespan and quality of life.

Objective

To assess comparative rates of diabetes development in patients in primary care population started on statin drugs; by comparing them with rates of diabetes development in patients also at high risk of cardiovascular disease started on blood pressure medications but not on statins, and with normal control group.

Methodology:

We will look at patients with first prescription of statin drugs and assess the proportion of users who develop diabetes in the subsequent 5 years. We will compare these rates in patients with first prescription of drugs for high blood pressure (high diabetes risk control group) and patients with none of these prescriptions (normal control group). Patients in the normal control group are those with without any of these prescriptions, and are recruited

from attendance for ACC-related conditions in the Canterbury region. We will use clinical data held electronically on drug prescriptions and laboratory tests on the Pegasus Health Community ePrescription system.

Study Design: Prospective cohort study using routinely collected data

Study population: Canterbury residents enrolled in Pegasus Health between ages 40 and 60, who are commenced on either on statin drugs, or on antihypertensives (high risk control group), or who have an ACC claim (low risk control group) in the years 2005 to 2007.

Exclusion: Patients who previously have diabetes, glucose intolerance, polycystic ovarian syndrome, and those who are already on metformin, thiazides and corticosteroids (all known to increase diabetes risk).

Other variables: From the clinical records where available the age, gender and sex; family history of diabetes; body mass index; LDL level measured; blood glucose or HbA1c measured; and smoking status. The purpose is to describe other cardiovascular risk factors, if any, for groups of patients with prescription for statin drugs or drugs for high blood pressure.

Follow up: Cohort will be followed up for 5 years.

Outcome measure: First prescription of Metformin, or HbA1c result indicating diabetes.

Analysis: Proportions compared between statin started, antihypertensives known to have increased diabetes risk (thiazides and beta-blocker), antihypertensives known to have no increased diabetic risk (ACE-inhibitors, ARBs, calcium channel blockers) and ACC control group.

Ethical considerations:

No ethics committee is required by the National Ethics Advisory Committee, New Zealand as stated in the *Ethical Guidelines for Observational Studies: Observational Research, Audits and Related Activities, NEAC, December 2006*.

Pegasus Health has a method for anonymously electronically extracting and linking these data. Patients are aware when they sign their enrolment form for Pegasus Health that their data may be used anonymously for quality improvement. Data will be de-identified at the point of extraction from the clinical record. Collection of such data will be stored in de-identified manner. This study has been approved for support by the Pegasus Health Research, Audit and Evaluation committee.

References:

1. Blackburn D, Wilson T. Antihypertensive medications and blood sugar: theories and implications. *Canadian Journal of Cardiology*. 2006;22(3):229-33.
2. Aksnes T, Reims H, Kjeldsen S, Mancina G. Antihypertensive Treatment and New Onset Diabetes Mellitus. *Current Hypertension Reports*. 2005;7:298-303.
3. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. *Archives of internal medicine*. 2012;172(2):144-52. Epub 2012/01/11.
4. Ridker P, Danielson E, Fonseca F, Genest J, Gotto A, Kastelein J, et al. Rosuvostatin to prevent vascular events in men and women with elevated CRP. *The New England Journal of Medicine*. 2008;359(21):2195-207.
5. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. *QJM : monthly journal of the Association of Physicians*. 2012;105(2):145-57. Epub 2011/09/17.
6. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. *QJM : monthly journal of the Association of Physicians*. 2011;104(2):109-24. Epub 2010/10/12.
7. Sattar N, Preiss D, Murray H, Welsh P, Buckley B, de Craen A, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *The Lancet*. 2010;375:735-42.
8. Cholesterol Treatment Trialists' collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. *Lancet*. 2005;366:1267-78.
9. Preiss D, Seshasai S, Welsh P, Murphy S, Ho J, Waters D, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A Meta-analysis. *JAMA*. 2011;305(4):2556-64.
10. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. *Current opinion in lipidology*. 2011;22(6):460-6. Epub 2011/09/08.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Check
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	✓ (refer Manuscript Page 1)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	✓ (refer Manuscript Page 4)
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	✓ (refer Manuscript Page 6)
Objectives	3	State specific objectives, including any prespecified hypotheses	✓ (refer Manuscript Page 6)
Methods			
Study design	4	Present key elements of study design early in the paper	✓ (refer Manuscript Page 7)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	✓ (refer Manuscript Page 7)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	✓ (refer Manuscript Page 7-8)
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	✓ (refer Manuscript Page 8)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	✓ (refer Manuscript Page 7)
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	✓ (refer Manuscript Page 8)
Statistical	12	(a) Describe all statistical methods, including those used to control	✓

1			
2	methods	for confounding	(refer Manuscript Page 8)
3			
4		(b) Describe any methods used to examine subgroups and interactions	✓ (refer Manuscript Page 8)
5			
6		(c) Explain how missing data were addressed	
7			
8		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	✓ (refer Manuscript Page 8)
9		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
10		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
11			
12		(e) Describe any sensitivity analyses	
13			
14	Participants	13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	✓ (refer Manuscript Page 9)
15		(b) Give reasons for non-participation at each stage	
16		(c) Consider use of a flow diagram	✓ (Figure 1, page 17 Manuscript)
17			
18	Descriptive data	14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	✓ (refer Manuscript Page 9, and table 1, page 19 Manuscript)
19		(b) Indicate number of participants with missing data for each variable of interest	✓
20		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	✓ (refer Manuscript Page 9)
21			
22	Outcome data	15* <i>Cohort study</i> —Report numbers of outcome events or summary measures over time	✓ (refer Manuscript Page 9)
23		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
24		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
25			
26	Main results	16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	✓ (refer Manuscript Page 9, Figure 2 and Table 2)
27		(b) Report category boundaries when continuous variables were categorized	
28		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
29			
30	Other analyses	17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	✓ (refer Manuscript Page 9)
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

			Page 10)
Discussion			
Key results	18	Summarise key results with reference to study objectives	✓ (refer Manuscript Page 11)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	✓ (refer Manuscript Page 12)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	✓ (refer Manuscript Page 13)
Generalisability	21	Discuss the generalisability (external validity) of the study results	✓ (refer Manuscript Page 13)
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	✓ (refer Manuscript Page 1)

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003475.R1
Article Type:	Research
Date Submitted by the Author:	27-Aug-2013
Complete List of Authors:	Currie, Olivia; Christchurch School of Medicine and Health Sciences, Public Health and General Practice Mangin, Dee; Christchurch School of Medicine and Health Sciences, Public Health and General Practice Williman, Jonathan; Christchurch School of Medicine and Health Sciences, Public Health and General Practice McKinnon-Gee, Bianca; Pegasus Health (Charitable) Limited, Bridgford, Paul; Pegasus Health (Charitable) Limited,
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Diabetes and endocrinology, Cardiovascular medicine
Keywords:	Audit < CARDIOLOGY, Lipid disorders < DIABETES & ENDOCRINOLOGY, PRIMARY CARE

SCHOLARONE™
Manuscripts

only

MANUSCRIPT

Title Page

Title

The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.

Authors

Olivia Currie, MBChB, DCH¹, Dee Mangin, MBChB, DPH, FRNZCGP¹, Jonathan Williman, PhD, GradDipBiostat¹, Bianca McKinnon-Gee, BA, BSc, BCom², Paul Bridgford, BSc².

1. Department of Public Health and General Practice, University of Otago, P.O. Box 4345, Christchurch 8140. New Zealand.

2. Pegasus Health (Charitable) Ltd. P O Box 741, Christchurch 8140. New Zealand

Corresponding author

Olivia Currie MBChB DCH, Department of Public Health and General Practice, University of Otago, P.O. Box 4345, Christchurch 8140. New Zealand. olivia.currie@otago.ac.nz

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

Word count

Abstract 295

Text 2949

Number of Tables

3

Number of figures

2

Key Words

Statins, diabetes, antihypertensives, metformin, primary care, electronic prescription.

Abbreviations

ACEi = angiotensin converting enzyme inhibitors

ARB = angiotensin II receptor blockers

CCB = calcium channel blockers

Study Groups:

Antihypertensives TB = thiazides and beta-blockers.

Antihypertensive AAC = angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers.

Abstract

Objective: Recent studies suggest statins increase the risk of subsequent diabetes with a clear dose response effect. However patients prescribed statins have a higher background risk of diabetes. This national cohort study aims to provide an estimate of the comparative risks for subsequent development of new-onset diabetes in adults prescribed statins, and those with already higher background risk on cardiovascular risk modifying drugs and a control drug.

Design: Longitudinal cohort study

Setting: Use of routinely collected data from a complete national primary care electronic prescription database in New Zealand.

Participants: 32,086 patients aged between 40 and 60 years in 2005 were eligible and assigned to four non-overlapping groups receiving their first prescription for:

1. diclofenac (healthy population) n=7140
2. antihypertensives thought likely to induce diabetes (thiazides and beta-blockers) n=5769
3. antihypertensives thought less likely to induce diabetes (ACEi, ARBs, CCBs) n= 6565
4. statins n= 12 612

Outcome: Numbers of first metformin prescriptions were compared between these groups from 2006 to 2011.

Results: Patients prescribed statins have the highest risk of receiving a subsequent metformin prescription (HR: 3.31; 95% CI: 2.56 to 4.30; P < 0.01), followed by patients prescribed antihypertensives thought less likely to induce diabetes (HR: 2.32; 95% CI: 1.74 to 3.09; P < 0.01) and patients prescribed

1
2
3
4
5 antihypertensives thought more likely to induce diabetes (HR: 1.59; 95% CI: 1.15 to 2.20; P < 0.01) in the
6
7 subsequent 6 years of follow up, when compared to diclofenac.
8
9

10 Conclusions: These findings further support the link between statin use and new-onset diabetes; and
11 suggest the understanding of diabetes risk associated with different antihypertensive drug classes may
12 bear practice modification. This provides important information for future research and for prescribers
13 and patients when considering the risks and benefits of different types of cardiovascular risk modifying
14
15
16
17
18
19
20 drugs.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Article focus:

- Estimates the comparative risks for subsequent development of new-onset diabetes in adults prescribed statins, other groups of cardiovascular risk modifying drugs indicating higher background risk and a control drug.

Key messages:

- Patients prescribed statins have the highest risk of receiving a subsequent metformin prescription (HR: 3.31; 95% CI: 2.56 to 4.30; $P < 0.01$) when compared to control drug
- Patients on antihypertensives are also likely to receive their first metformin prescription when prescribed ACEi, ARB and CCB (HR: 2.32; 95% CI: 1.74 to 3.09; $P < 0.01$), and thiazides and beta-blockers (HR: 1.59; 95% CI: 1.15 to 2.20; $P < 0.01$) compared to control drug. However, this risk is not as high as those on statins.

Strengths:

- A national cohort study using electronic prescription database
- First longitudinal study to compare incidence of subsequent diabetes between statins and antihypertensives with a control drug
- First study to measure outcome by proxy of first metformin prescription as indication of significant diabetes development.

Limitations:

- Confounding factors like BMI, family history and socioeconomic status is not controlled for in this electronic database analysis. However, there is no indication that these factors are not unevenly distributed between the different “high risk” study groups.
- There is a small risk of misclassification for prescription of metformin for other conditions such as polycystic ovary syndrome and extreme insulin resistance with acanthosis nigricans, but these are rare and are likely to only account for a small number of prescriptions.

For peer review only

Text

Introduction

Statins are widely used and have established benefits in the prevention of cardiovascular events.¹ However, recent studies suggested statins may also increase the risk of new-onset diabetes²⁻⁸, which in turn increases risk of cardiovascular events. One meta-analysis reported the odds to be 9% (OR: 1.09; 95% Confidence Interval (CI) 1.02 to 1.17)⁵, with other studies showing the association with pravastatin and rosuvostatin use.^{3,4,7,9-11} More recent data indicates the risk of new-onset diabetes with statin use could also be dose dependent, further supporting a causal link.⁶ Nevertheless, statins may still have an overall cardiovascular benefit.⁵

One of the difficulties in assessing the extent of this risk is that the patients with higher cardiovascular risk who are prescribed statins also carry an increased baseline risk of developing diabetes because of similar risk factors.¹²⁻¹⁴ To understand the extent of the contributions of this increased baseline risk and the risk from the drugs themselves, we compared subsequent diabetes development in patients started on a statin with that in patients started on other drugs for cardiovascular risk management (antihypertensives) and with patients at low baseline risk. We used a complete national prescribing dataset¹⁵ to create a population based cohort constructed of these three groups and compared the risk of subsequent development of clinically significant diabetes in each group.

Methods

Study design: Longitudinal cohort study using a national data set of de-identified routinely collected primary care electronic prescriptions of New Zealanders between ages 40 and 60, receiving first prescriptions of drugs studied (Appendix 1) in the year 2005.

Data source: Nationwide prescription data for the purpose of this study were sourced electronically from a complete national prescribing dataset, the New Zealand Health Information Service' (NZHIS) Pharmaceutical Collection.¹⁶ Community prescribing is electronic in primary care in New Zealand making this information accessible via NZHIS. Individual patients are assigned a unique identifier (NHI number) in

1
2
3
4
5 the New Zealand health system and this is attached to their prescriptions, allowing this to be the main
6
7 data key linkage tool. All NHIs were de-identified at the point of data extraction, and automatically
8
9 assigned a unique encrypted code.
10

11 Cohort construction: The cohort construction is illustrated in Figure 1 (Flow chart of cohort formation). The
12
13 cohort included patients aged 40-60 in the year 2005 without prior prescription of excluded drugs and
14
15 metformin (outcome drug) (Appendix 1), and all patients having received a prescription of at least one of
16
17 the drugs of interest between 2005 and 2011. These drugs were statins, antihypertensives, diclofenac
18
19 (comparator drug) or metformin (outcome drug). Diclofenac was chosen as the comparator drug to
20
21 represent low diabetic risk patients presenting to primary care services with musculoskeletal injuries.
22
23 Some antihypertensives are associated with subsequent development of diabetes. Thiazide diuretics (T)
24
25 and beta-blockers (BB) are most strongly associated with an increased risk,^{14,17-19} whereas little association
26
27 has been made with angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers
28
29 (ARB) and calcium channel blockers (CCB).^{18,19} Following the literature, those in the antihypertensive drug
30
31 group were further divided into “Antihypertensives TB” for antihypertensives thought likely to increase
32
33 diabetes risk (T and BB), and “Antihypertensives AAC” for antihypertensives thought less likely to do so
34
35 (ACEi, ARB and CCB). A total of 195,194 records listed at least one of the drugs in the drug groups under
36
37 study: Diclofenac, Antihypertensives TB, Antihypertensives AAC, and Statin groups. Patients belonging to
38
39 two study groups concurrently in 2005 were then excluded. Data were further examined and cleaned to
40
41 identify duplicate individuals, exclusion drugs and data entry error. This left 32,086 unique individuals to
42
43 form the 2005 study cohort with 7140, 5769, 6565 and 12,612 in Diclofenac, Antihypertensives TB,
44
45 Antihypertensives AAC, Statin groups respectively.
46
47
48
49
50
51

52 Exclusion: Patients who had a prescription for oral hypoglycaemics, insulin, oral corticosteroids (known to
53
54 increase the risk of diabetes), or any of the study group medications of interest (Appendix 1) prior to 2005.
55
56 The upper age limit was chosen to limit the inclusion of cardiovascular drugs prescribed for treatment of
57
58 other cardiovascular conditions (e.g. heart failure).
59
60

1
2
3
4
5 Exposure: New Zealand adults who received their first prescription of statins, antihypertensives, or
6
7 diclofenac in the calendar year 2005 without prior prescription of exclusion drugs and metformin.

8
9
10 Primary Outcome Measure: The proportion of patients receiving their first prescription of metformin in
11
12 the calendar years 2006-2011. Metformin is the recommended first line treatment for newly diagnosed
13
14 type 2 diabetes mellitus in New Zealand.²⁰

15
16
17 Analysis: Patient baseline demographics were summarised using simple descriptive statistics and
18
19 differences between cohorts were assessed using chi-square statistics calculated on OpenEpi online²¹.
20
21 Since these are routinely collected electronic records, loss to follow up cannot be measured directly, and
22
23 will be measured by proxy of medication persistence, death and emigration rate. Persistence with
24
25 medications was determined as having at least one prescription a year, and persons-years were calculated
26
27 based on this data. Death and emigration rate were calculated by direct age standardisation based on
28
29 information available on Statistics New Zealand life-tables to estimate loss to follow up for our cohorts.²²
30
31 Incidence rates and hazard ratios (HR) with 95% confidence intervals (95% CI) were calculated to compare
32
33 the risk of new-onset diabetes between Diclofenac group and the other three cohorts. HR were calculated
34
35 in SPSS 20.0 for Windows (SPSS Inc) using cox proportional hazards regression, and multivariable analysis
36
37 was used to adjust for differences in the demographic structure of the cohorts. All analyses were 2-sided.
38
39
40
41
42
43

44 **Results:**

45
46 Patient characteristics: The baseline characteristics of the cohorts are summarised in Table 1 (Cohort
47
48 demographic). The sex of the patients differed by groups with a higher proportion of females (68.8%, $\chi^2(1)$
49
50 = 447.86 , p < 0.001) in the Antihypertensives TB group, and of males (66.6%, $\chi^2(1) = 545.35$, p < 0.001) in
51
52 the statin group. The age of patients also differed across groups with patients receiving cardiovascular risk
53
54 modifying drugs tending to be older than those in the diclofenac group ($\chi^2(1) = 1016.39$, p < 0.001). New
55
56 Zealand European was the major ethnicity in all study groups. There were more Maori in the Diclofenac
57
58 group with only a few in the statin group ($\chi^2(1) = 301.86$, p < 0.001). These differences between groups are
59
60 adjusted for in the multivariable analysis.

1
2
3
4
5 Cohort characteristics and follow up: A total of 32,086 unique patients were eligible for analysis from the
6
7 recruitment: 7140 for the Diclofenac group, 5769 for Antihypertensives TB group, 6565 for
8
9 Antihypertensives AAC group, and 12,612 for the Statin group (Figure 1). Persistence with index
10
11 medications for each group was 38.4%, 71.3%, 70.9% and 76.1% respectively (Appendix 2). The persistence
12
13 within the control group was expectedly lower as diclofenac is not usually indicated for long term use. Loss
14
15 of follow up due to deaths and emigration is estimated to be less than 2% of those who were not
16
17 persistent with medications, assuming death and emigration rate were similar to the overall New Zealand
18
19 population within similar age groups during the study period.
20
21

22 Primary analysis: Primary outcome results indicated that between 2006 and 2011, 710 patients within the
23
24 four groups received their first prescription of metformin. This represents 1.2%, 1.5%, 2.3% and 3.1% of
25
26 those exposed to Diclofenac, Antihypertensives TB, Antihypertensives AAC and Statin groups respectively.
27
28 The incidence rates were 2.5, 2.8, 4.2 and 5.5 cases per 1,000 person years for first prescription of
29
30 metformin (Table 2) accordingly. In the multivariable analysis, patients commenced on statins had the
31
32 highest risk of receiving a first prescription of metformin in 6 years after exposure compared to the Control
33
34 group (HR: 3.31; 95% CI: 2.56-4.30elevated; P < 0.01). In contrast to existing research, when compared to
35
36 patients on diclofenac, patients on Antihypertensives AAC group have moderate risk of receiving their first
37
38 prescription of metformin in 6 years (HR: 2.32; 95% CI: 1.74-3.09; P < 0.01), and patients in the
39
40 Antihypertensives TB group had a slightly elevated risk (HR: 1.59; 95% CI: 1.15-2.20; P < 0.01) (Table 3).
41
42 Our analysis indicates a duration-response: The HR of developing new-onset diabetes was approximately
43
44 constant over the duration of the study as demonstrated by the plot for the cumulative hazard ratios for
45
46 the first metformin prescription in each study cohort (Figure 2), adjusting for age, sex, and ethnicity.
47
48

49 Subgroup analyses: Patient demographics were analysed to assess other characteristics of recipients of
50
51 first metformin prescription (Appendix 3). Cox regression model analysis revealed that females had a lower
52
53 risk than males (HR = 0.85, 95% CI: 0.72-1.00, p = 0.05), and there was no difference in risk between age
54
55 groups within our cohort age range. However, risks were increased with all other ethnicities when
56
57
58
59
60

1
2
3
4
5 compared to New Zealand European. Pacific Island and Asian ethnic group had the highest risk at HR 3.57
6
7 (95%CI: 2.63-4.85, P < 0.01) and HR 3.72 (95% CI: 3.00-4.62, P<0.01) respectively.

8
9
10 To assess whether those at risk of developing diabetes were prescribed higher doses of their prescribed
11
12 medications, the drug doses of their first prescribed indexed medications in 2005 among those prescribed
13
14 metformin were assessed. In the Statin group, 96.9% of patients were prescribed 40mg and less of both
15
16 simvastatin and atorvastatin. For patients in the Antihypertensives TB group, 78.8% of patients were on
17
18 beta blockers and 88% of those on thiazides were on 2.5mg of bendrofluazide. This indicates patients
19
20 commenced on metformin were prescribed conservative dosing of cardiovascular risk modifying drugs.

21
22
23 There were 743 patients who swapped study cohorts during the study period. Of these, 220 were from the
24
25 Diclofenac group, 206 from Antihypertensives TB group, 166 from Antihypertensives AAC group and 151
26
27 from Statin group (Appendix 4). Excluding these patients in a per-protocol analysis had little effect on the
28
29 hazard ratios compared to the intention to treat analysis (results of analysis available but not included),
30
31 which could indicate the effect is rare or that the exposure is steady.
32
33
34
35
36

37 Discussion

38
39 Patients on any cardiovascular risk modifying drugs had a higher risk of new-onset diabetes compared to
40
41 patients receiving diclofenac. Patients receiving a first prescription for statins were at the highest risk of
42
43 subsequently developing clinically significant diabetes, with a risk three times that of those prescribed
44
45 diclofenac. Patients prescribed ACE inhibitors, ARBs or calcium channel blockers were the next highest risk,
46
47 being twice as likely to receive a metformin prescription, while those prescribed thiazides and beta-
48
49 blockers were only at slightly increased risk.
50
51

52
53 The association between new-onset diabetes, as estimated by first metformin prescriptions, and initiation
54
55 of statins found in this study is consistent with recent reports. However, the risk in this population was
56
57 lower (3.1%) than the 9% risk reported in meta-analyses.²³⁻²⁵ More recent publications have identified the
58
59 risks of new-onset diabetes with statin drug use ranging from 2.4% to 8.5%.²³⁻²⁶ In contrast to our study,
60
the diagnosis of diabetes in these other studies were identified by indicators such as disease classification

1
2
3
4
5 recording, or intermediate indicators such as laboratory investigations of HbA1c and fasting serum glucose
6
7 readings. This will draw in milder levels of hyperglycemia where lifestyle changes can still be the first line
8
9 of management and where laboratory threshold determines disease rates. This study is the first to identify
10
11 the incident rate of clinically significant diabetes in patients prescribed statins as indicated by the first
12
13 prescription of metformin in a non-research population. This is an outcome that matters to patients.

14
15
16 Our study is also the first to compare the risks of diabetes development in patients on statins against
17
18 patients on other cardiovascular risk modifying drugs who might also be considered to be 'high risk'.
19
20 Patients initiated on antihypertensive drugs were, like those prescribed statins, at greater risk of
21
22 developing diabetes compared to those on diclofenac. Our findings therefore allow an assessment of the
23
24 comparative risks of new-onset diabetes in patients with already higher risk on different classes of
25
26 antihypertensives. There may be several explanations for the differences seen. Firstly, it may be a true
27
28 association. Secondly, it may be that patients with risk factors for diabetes (such as obesity) are less likely
29
30 to be prescribed treatment with associated increased risk of diabetes.^{14,27} Hence, they are more likely to
31
32 receive prescriptions of ACEi or ARBs for management of hypertension due to a lesser known risk of
33
34 inducing diabetes. We also observed conservative dosing in patients on thiazides and beta-blockers, which
35
36 may attenuate the risk. Presence of metabolic syndrome risk factors also increased the risk of subsequent
37
38 glucose elevation, on as well as off statin use.²⁸ This study is not able to answer these questions, but raises
39
40 these for future research.

41
42
43 Since all data collected are electronic records, patient persistence with medication can be grossly assessed.
44
45 There were high rates of persistence with medications within the study groups, in particular to the
46
47 antihypertensives and the statins. Given only a total of 743 patients (2.3% of 2005 cohort) swapped into
48
49 different study groups during the study period, there were relatively clean groups for analyses of risks.

50
51
52 The development of clinically significant diabetes was estimated using a proxy measure, utilising the first
53
54 prescription of metformin. The validity of using routinely collected and electronically stored prescription
55
56 data for diagnosing diabetes has been previously demonstrated.^{15,29} The use of routinely collected data
57
58 also provides access to a complete national population based cohort. We were able to assess this cohort
59
60

1
2
3
4
5 longitudinally over a period of 6 years in a representative primary care population rather than a trial
6
7 population with tightly constrained entry criteria.

9 10 **Limitations**

11
12 Our study has several limitations. The nature of the electronic datasets available means it is not possible to
13
14 obtain other factors contributing to cardiovascular and diabetes risks to more precisely define subgroups
15
16 and allow direct comparison of the cohorts' baseline levels of risk of developing diabetes (e.g. body mass
17
18 index and family history). These are major uncontrolled confounding and effect modifiers that cannot be
19
20 accounted for in this study.

21
22
23 There is also the risk of misclassification. Metformin may also be prescribed for management of other
24
25 conditions such as polycystic ovary syndrome and extreme insulin resistance with acanthosis nigricans,
26
27 however this is likely to account for only a small proportion of prescriptions. With first prescription of
28
29 metformin, we have also excluded patients who present infrequently to their primary health care
30
31 providers for well-checks and routine follow up (missing new-onset diabetes) and those who may have
32
33 presented acutely with diabetic emergency (as they will be commenced on alternate hypoglycaemic
34
35 agents).

36
37
38 It is also uncertain as to how frequently these patients are tested for diabetes mellitus in the primary care
39
40 setting, as the electronic system is not currently linked to laboratory data. The study is also unable to
41
42 control for the duration of mild hyperglycaemia prior to commencement of metformin.

43
44
45 In this study, we have not distinguished between the various statin doses and formulations.

46 47 48 49 50 **Conclusions**

51
52 Patients initiating treatment with any of the index cardiovascular risk modifying drugs have some risk of
53
54 developing clinically significant new-onset diabetes compared to those prescribed diclofenac. However,
55
56 patients prescribed statins have the highest risk of new-onset diabetes, strengthening the recent signal
57
58 from current literature. Patients prescribed ACE inhibitors, angiotensin II receptor blockers and calcium
59
60 channel blockers were also at moderately increased risk, while patients prescribed thiazides and beta-

1
2
3
4
5 blockers only appeared to have a mildly increased risk. The effect seen carries an exposure duration-
6
7 response groups, and is also seen in patients prescribed relatively low doses of these drugs, which is
8
9 important information for prescribers. This provides additional information on the comparative safety of
10
11 these drugs in a real world setting in primary care, where the bulk of these prescriptions are likely to be
12
13 initiated. This is useful information for doctors and patients considering the balance of harms against the
14
15 potential for benefit of both statins and different cardiovascular risk modifying medications in different
16
17 populations.
18
19
20
21
22

23 **Further Research**

24
25 Whether there is an additive risk of inducing diabetes with combinations of different cardiovascular risk
26
27 modifying drugs is currently unknown, and an important area for research to inform decision making on
28
29 prescribing, given the prevalence of multi-morbidity and likely co-prescription. This is subject to a further
30
31 study. It is also unclear what effect this additional risk of diabetes will have on morbidity and mortality for
32
33 patients. Diabetes, as a diagnosis based on a measurement, is itself a source of morbidity and mortality
34
35 largely only as a risk factor for other disease, predominantly cardiovascular disease.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Prior Presentations

None

Ethics Application

As all data were de-identified by encryption, ethics approval was confirmed as not required by the National Ethics Advisory Committee, New Zealand as stated in the *Ethical Guidelines for Observational Studies: Observational Research, Audits and Related Activities, NEAC, December 2006* (Upper South B Regional Ethics Committee, Ethics ref: URB/12/EXP/022).

Acknowledgements

We thank the Canterbury Chair of General Practice Trust (Inc.) for the sponsoring the role of the General Practice Research Registrar for this project. We also thank the University of Otago, New Zealand for providing all computing softwares.

Conflict of Interest Statement

None

Prior Publication

None

Data Sharing

Technical appendix, statistical code, and dataset available from the corresponding author at Dryad repository, who will provide a permanent, citable and open access home for the dataset.

Contributorship

Olivia Currie, Dee Mangin, Bianca McKinnon-Gee and Paul Bridgford design the study. Bianca McKinnon-Gee ran the search for electronic prescription data according to study protocol. Olivia Currie designed data

1
2
3
4
5 collection tools, monitored data collection for the whole study, wrote the statistical analysis plan, cleaned
6
7 and analysed the data, and drafted and revised the paper. Olivia Currie and Jonathan Williman analysed
8
9 the data. Olivia Currie, Dee Mangin and Jonathan Williman revised the draft paper.
10
11
12
13
14
15
16
17
18

19 References

- 20
21
22 1. Taylor F HM, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the
23 primary prevention of cardiovascular disease. . *Cochrane Database of Systematic Reviews*.
24 2013(1):Art. No.: CD004816.
25
26
- 27
28 2. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in
29 postmenopausal women in the Women's Health Initiative. *Archives of internal medicine*. Jan 23
30 2012;172(2):144-152.
31
32
- 33
34 3. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin
35 treatments for cardiovascular disease: an indirect comparison meta-analysis. *QJM : monthly*
36 *journal of the Association of Physicians*. Feb 2012;105(2):145-157.
37
38
- 39
40 4. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a
41 network meta-analysis of 170,255 patients from 76 randomized trials. *QJM : monthly journal of the*
42 *Association of Physicians*. Feb 2011;104(2):109-124.
43
44
- 45
46 5. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. *Current*
47 *opinion in lipidology*. Dec 2011;22(6):460-466.
48
49
- 50
51 6. Preiss D, Seshasai S, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with
52 moderate-dose statin therapy: A Meta-analysis. *JAMA*. 2011;305(4):2556-2564.
53
54
- 55
56 7. Sattar N, Preiss D, Murray H, et al. Statins and risk of incident diabetes: a collaborative meta-
57 analysis of randomised statin trials. *The Lancet*. 2010;375:735-742.
58
59
60

- 1
2
3
4
5 **8.** Ridker P, Danielson E, Fonseca F, et al. Rosuvostatin to prevent vascular events in men and women
6 with elevated CRP. *The New England Journal of Medicine*. 2008;359(21):2195-2207.
7
- 8
9 **9.** Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in
10 hypercholesterolemic patients. *Atherosclerosis*. Jun 2009;204(2):483-490.
11
- 12 **10.** Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and
13 increases ambient glycemia in hypercholesterolemic patients. *Journal of the American College of*
14 *Cardiology*. Mar 23 2010;55(12):1209-1216.
15
- 16 **11.** Cholesterol Treatment Trialists' collaborators. Efficacy and safety of cholesterol-lowering
17 treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of
18 statins. *Lancet*. 2005;366:1267-1278.
19
- 20 **12.** Movahed MR, Sattur S, Hashemzadeh M. Independent association between type 2 diabetes
21 mellitus and hypertension over a period of 10 years in a large inpatient population. *Clin Exp*
22 *Hypertens*. May 2010;32(3):198-201.
23
- 24 **13.** Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L. Adverse prognostic
25 significance of new diabetes in treated hypertensive subjects. *Hypertension*. 2004;43:963-969.
26
- 27 **14.** Dagenais GR AP, Bogaty P, Gerstein H, Lonn E, Yi Q, Yusuf S. Increased occurrence of diabetes in
28 people with ischemic cardiovascular disease and general and abdominal obesity. *Can J Cardiol*.
29 2003;19:1387-1391.
30
- 31 **15.** Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and
32 Wales: population based cohort study using QResearch database. *BMJ*. 2010;49:340.
33
- 34 **16.** Source: Ministry of Health, Pharmaceutical Collection.
35
- 36 **17.** Smith SM, Gong Y, Turner ST, et al. Blood pressure responses and metabolic effects of
37 hydrochlorothiazide and atenolol. *American journal of hypertension*. Mar 2012;25(3):359-365.
38
- 39 **18.** Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. *Journal of*
40 *Hypertension*. 2006;24:3-10.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5 19. Aksnes T, Reims H, Kjeldsen S, Mancia G. Antihypertensive Treatment and New Onset Diabetes
6 Mellitus. *Current Hypertension Reports*. 2005;7:298-303.
7
- 8
9 20. New Zealand Guidelines Group. New Zealand Primary Care Handbook 2012. 3rd ed. Wellington:
10 New Zealand Guidelines Group; 2012.
11
- 12 21. Dean AG SK, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version
13 2.3.1. www.OpenEpi.com, updated 2011/23/06, accessed 2012/10/23.
14
15
- 16 22. Statistics New Zealand. <http://www.stats.govt.nz/infoshare>.
17
- 18 23. Wang K-L, Liu C-J, Chao T-F, et al. Statins, Risk of Diabetes, and Implications on Outcomes in the
19 General Population. *Journal of the American College of Cardiology*. 2012;60(14):1231-1238.
20
- 21 24. Rautio N, Jokelainen J, Oksa H. Do statins interfere with lifestyle intervention in the prevention of
22 diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. *BMJ Open*. 2012;2(5).
23
24
- 25 25. Ma T, Tien L, Fang C-L, Liou Y-S, Jong G-P. Statins and New-Onset Diabetes: A Retrospective
26 Longitudinal Cohort Study. *Clinical Therapeutics*. 2012;34(9):1977-1983.
27
28
- 29 26. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes
30 among patients treated with statins: population based study. *BMJ*. 2013:346.
31
32
- 33 27. Abdullah A, Stoelwinder J, Shortreed S, et al. The duration of obesity and the risk of type 2
34 diabetes. *Public health nutrition*. Jan 2011;14(1):119-126.
35
36
- 37 28. Golomb BA, Koperski S WH. Statins Raise Glucose Preferentially among Men who are Older and at
38 Greater Metabolic Risk. *Epidemiology and Prevention; Nutrition , Physical Activity and Metabolism*
39 *2012 Scientific Sessions*. San Diego, CA.2012.
40
41
- 42 29. Tu K. Diabetics can be identified in an electronic medical record using laboratory tests and
43 prescriptions. *J Epi*. 2011;64(4):431-435.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MANUSCRIPT

Title Page

Title

The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.

Authors

Olivia Currie, MBChB, DCH¹, Dee Mangin, MBChB, DPH, FRNZCGP¹, Jonathan Williman, PhD, GradDipBiostat¹, Bianca McKinnon-Gee, BA, BSc, BCom², Paul Bridgford, BSc².

1. Department of Public Health and General Practice, University of Otago, P.O. Box 4345, Christchurch 8140. New Zealand.

2. Pegasus Health (Charitable) Ltd. P O Box 741, Christchurch 8140. New Zealand

Corresponding author

Olivia Currie MBChB DCH, Department of Public Health and General Practice, University of Otago, P.O. Box 4345, Christchurch 8140. New Zealand. olivia.currie@otago.ac.nz

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Prior Presentations

None

Word count

Abstract 295

Text 2949

Number of Tables

3

Number of figures

2

Ethics Application

As all data were de-identified by encryption, ethics approval was confirmed as not required by the National Ethics Advisory Committee, New Zealand as stated in the *Ethical Guidelines for Observational Studies: Observational Research, Audits and Related Activities, NEAC, December 2006* (Upper South B Regional Ethics Committee, Ethics ref: URB/12/EXP/022).

Acknowledgements

We thank the Canterbury Chair of General Practice Trust (Inc.) for the sponsoring the role of the General Practice Research Registrar for this project. We also thank the University of Otago, New Zealand for providing all computing softwares.

Conflict of Interest Statement

None

Prior Publication

None

Data Sharing

Technical appendix, statistical code, and dataset available from the corresponding author at Dryad repository, who will provide a permanent, citable and open access home for the dataset.

Key Words

Statins, diabetes, antihypertensives, metformin, primary care, electronic prescription.

Abbreviations

ACEi = angiotensin converting enzyme inhibitors

ARB = angiotensin II receptor blockers

CCB = calcium channel blockers

Study Groups:

Antihypertensives TB = thiazides and beta-blockers.

1
2
3
4
5 Antihypertensive AAC = angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium
6
7 channel blockers.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objective: Recent studies suggest statins increase the risk of subsequent diabetes with a clear dose response effect. However patients prescribed statins have a higher background risk of diabetes. This national cohort study aims to provide an estimate of the comparative risks for subsequent development of new-onset diabetes in adults prescribed statins, and those with already higher background risk on cardiovascular risk modifying drugs and a control drug.

Design: Longitudinal cohort study

Setting: Use of routinely collected data from a complete national primary care electronic prescription database in New Zealand.

Participants: 32,086 patients aged between 40 and 60 years in 2005 were eligible and assigned to four non-overlapping groups receiving their first prescription for:

1. diclofenac (healthy population) n=7140
2. antihypertensives thought likely to induce diabetes (thiazides and beta-blockers) n=5769
3. antihypertensives thought less likely to induce diabetes (ACEi, ARBs, CCBs) n= 6565
4. statins n= 12 612

Outcome: Numbers of first metformin prescriptions were compared between these groups from 2006 to 2011.

Results: Patients prescribed statins have the highest risk of receiving a subsequent metformin prescription (HR: 3.31; 95% CI: 2.56 to 4.30; P < 0.01), followed by patients prescribed antihypertensives thought less likely to induce diabetes (HR: 2.32; 95% CI: 1.74 to 3.09; P < 0.01) and patients prescribed

1
2
3
4
5 antihypertensives thought more likely to induce diabetes (HR: 1.59; 95% CI: 1.15 to 2.20; P < 0.01) in the
6
7 subsequent 6 years of follow up, when compared to diclofenac.
8
9

10 Conclusions: These findings further support the link between statin use and new-onset diabetes; and
11 suggest the understanding of diabetes risk associated with different antihypertensive drug classes may
12 bear practice modification. This provides important information for future research and for prescribers
13 and patients when considering the risks and benefits of different types of cardiovascular risk modifying
14
15
16
17
18
19
20 drugs.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Article focus:

- Estimates the comparative risks for subsequent development of new-onset diabetes in adults prescribed statins, other groups of cardiovascular risk modifying drugs indicating higher background risk and a control drug.

Key messages:

- Patients prescribed statins have the highest risk of receiving a subsequent metformin prescription (HR: 3.31; 95% CI: 2.56 to 4.30; P < 0.01) when compared to control drug
- Patients on antihypertensives are also likely to receive their first metformin prescription when prescribed ACEi, ARB and CCB (HR: 2.32; 95% CI: 1.74 to 3.09; P < 0.01), and thiazides and beta-blockers (HR: 1.59; 95% CI: 1.15 to 2.20; P < 0.01) compared to control drug. However, this risk is not as high as those on statins.

Strengths:

- A national cohort study using electronic prescription database
- First longitudinal study to compare incidence of subsequent diabetes between statins and antihypertensives with a control drug
- First study to measure outcome by proxy of first metformin prescription as indication of significant diabetes development.

Limitations:

- Confounding factors like BMI, family history and socioeconomic status is not controlled for in this electronic database analysis. However, there is no indication that these factors are not unevenly distributed between the different “high risk” study groups.
- There is a small risk of misclassification for prescription of metformin for other conditions such as polycystic ovary syndrome and extreme insulin resistance with acanthosis nigricans, but these are rare and are likely to only account for a small number of prescriptions.

For peer review only

Text

Introduction

Statins are widely used and have established benefits in the prevention of cardiovascular events.¹ However, recent studies suggested statins may also increase the risk of new-onset diabetes²⁻⁸, which in turn increases risk of cardiovascular events. One meta-analysis reported the odds to be 9% (OR: 1.09; 95% Confidence Interval (CI) 1.02 to 1.17)⁵, with other studies showing the association with pravastatin and rosuvastatin use.^{3,4,7,9-11} More recent data indicates the risk of new-onset diabetes with statin use could also be dose dependent, further supporting a causal link.⁶ Nevertheless, statins may still have an overall cardiovascular benefit.⁵

One of the difficulties in assessing the extent of this risk is that the patients with higher cardiovascular risk who are prescribed statins also carry an increased baseline risk of developing diabetes because of similar risk factors.¹²⁻¹⁴ To understand the extent of the contributions of this increased baseline risk and the risk from the drugs themselves, we compared subsequent diabetes development in patients started on a statin with that in patients started on other drugs for cardiovascular risk management (antihypertensives) and with patients at low baseline risk. We used a complete national prescribing dataset¹⁵ to create a population based cohort constructed of these three groups and compared the risk of subsequent development of clinically significant diabetes in each group.

Methods

Study design: Longitudinal cohort study using a national data set of de-identified routinely collected primary care electronic prescriptions of New Zealanders between ages 40 and 60, receiving first prescriptions of drugs studied (Appendix 1) in the year 2005.

Data source: Nationwide prescription data for the purpose of this study were sourced electronically from a complete national prescribing dataset, the New Zealand Health Information Service' (NZHIS) Pharmaceutical Collection.¹⁶ Community prescribing is electronic in primary care in New Zealand making this information accessible via NZHIS. Individual patients are assigned a unique identifier (NHI number) in

1
2
3
4
5 the New Zealand health system and this is attached to their prescriptions, allowing this to be the main
6
7 data key linkage tool. All NHIs were de-identified at the point of data extraction, and automatically
8
9 assigned a unique encrypted code.
10

11 Cohort construction: The cohort construction is illustrated in Figure 1 (Flow chart of cohort formation). The
12
13 cohort included patients aged 40-60 in the year 2005 without prior prescription of excluded drugs and
14
15 metformin (outcome drug) (Appendix 1), and all patients having received a prescription of at least one of
16
17 the drugs of interest between 2005 and 2011. These drugs were statins, antihypertensives, diclofenac
18
19 (comparator drug) or metformin (outcome drug). Diclofenac was chosen as the comparator drug to
20
21 represent low diabetic risk patients presenting to primary care services with musculoskeletal injuries.
22
23

24
25 Some antihypertensives are associated with subsequent development of diabetes. Thiazide diuretics (T)
26
27 and beta-blockers (BB) are most strongly associated with an increased risk,^{14,17-19} whereas little association
28
29 has been made with angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers
30
31 (ARB) and calcium channel blockers (CCB).^{18,19} Following the literature, those in the antihypertensive drug
32
33 group were further divided into “Antihypertensives TB” for antihypertensives thought likely to increase
34
35 diabetes risk (T and BB), and “Antihypertensives AAC” for antihypertensives thought less likely to do so
36
37 (ACEi, ARB and CCB). A total of 195,194 records listed at least one of the drugs in the drug groups under
38
39 study: Diclofenac, Antihypertensives TB, Antihypertensives AAC, and Statin groups. Patients belonging to
40
41 two study groups concurrently in 2005 were then excluded. Data were further examined and cleaned to
42
43 identify duplicate individuals, exclusion drugs and data entry error. This left 32,086 unique individuals to
44
45 form the 2005 study cohort with 7140, 5769, 6565 and 12,612 in Diclofenac, Antihypertensives TB,
46
47 Antihypertensives AAC, Statin groups respectively.
48
49
50
51

52
53 Exclusion: Patients who had a prescription for oral hypoglycaemics, insulin, oral corticosteroids (known to
54
55 increase the risk of diabetes), or any of the study group medications of interest (Appendix 1) prior to 2005.
56
57 The upper age limit was chosen to limit the inclusion of cardiovascular drugs prescribed for treatment of
58
59 other cardiovascular conditions (e.g. heart failure).
60

1
2
3
4
5 Exposure: New Zealand adults who received their first prescription of statins, antihypertensives, or
6
7 diclofenac in the calendar year 2005 without prior prescription of exclusion drugs and metformin.
8

9
10 Primary Outcome Measure: The proportion of patients receiving their first prescription of metformin in
11
12 the calendar years 2006-2011. Metformin is the recommended first line treatment for newly diagnosed
13
14 type 2 diabetes mellitus in New Zealand.²⁰
15

16
17 Analysis: Patient baseline demographics were summarised using simple descriptive statistics and
18
19 differences between cohorts were assessed using chi-square statistics calculated on OpenEpi online²¹.
20
21 Since these are routinely collected electronic records, loss to follow up cannot be measured directly, and
22
23 will be measured by proxy of medication persistence, death and emigration rate. Persistence with
24
25 medications was determined as having at least one prescription a year, and persons-years were calculated
26
27 based on this data. Death and emigration rate were calculated by direct age standardisation based on
28
29 information available on Statistics New Zealand life-tables to estimate loss to follow up for our cohorts.²²
30
31 Incidence rates and hazard ratios (HR) with 95% confidence intervals (95% CI) were calculated to compare
32
33 the risk of new-onset diabetes between Diclofenac group and the other three cohorts. HR were calculated
34
35 in SPSS 20.0 for Windows (SPSS Inc) using cox proportional hazards regression, and multivariable analysis
36
37 was used to adjust for differences in the demographic structure of the cohorts. All analyses were 2-sided.
38
39
40
41
42
43

44 **Results:**

45
46 Patient characteristics: The baseline characteristics of the cohorts are summarised in Table 1 (Cohort
47
48 demographic). The sex of the patients differed by groups with a higher proportion of females (68.8%, $\chi^2(1)$
49
50 = 447.86 , p < 0.001) in the Antihypertensives TB group, and of males (66.6%, $\chi^2(1) = 545.35$, p < 0.001) in
51
52 the statin group. The age of patients also differed across groups with patients receiving cardiovascular risk
53
54 modifying drugs tending to be older than those in the diclofenac group ($\chi^2(1) = 1016.39$, p < 0.001). New
55
56 Zealand European was the major ethnicity in all study groups. There were more Maori in the Diclofenac
57
58 group with only a few in the statin group ($\chi^2(1) = 301.86$, p < 0.001). These differences between groups are
59
60 adjusted for in the multivariable analysis.

1
2
3
4
5 Cohort characteristics and follow up: A total of 32,086 unique patients were eligible for analysis from the
6
7 recruitment: 7140 for the Diclofenac group, 5769 for Antihypertensives TB group, 6565 for
8
9 Antihypertensives AAC group, and 12,612 for the Statin group (Figure 1). Persistence with index
10
11 medications for each group was 38.4%, 71.3%, 70.9% and 76.1% respectively (Appendix 2). The persistence
12
13 within the control group was expectedly lower as diclofenac is not usually indicated for long term use. Loss
14
15 of follow up due to deaths and emigration is estimated to be less than 2% of those who were not
16
17 persistent with medications, assuming death and emigration rate were similar to the overall New Zealand
18
19 population within similar age groups during the study period.
20
21

22 Primary analysis: Primary outcome results indicated that between 2006 and 2011, 710 patients within the
23
24 four groups received their first prescription of metformin. This represents 1.2%, 1.5%, 2.3% and 3.1% of
25
26 those exposed to Diclofenac, Antihypertensives TB, Antihypertensives AAC and Statin groups respectively.
27
28 The incidence rates were 2.5, 2.8, 4.2 and 5.5 cases per 1,000 person years for first prescription of
29
30 metformin (Table 2) accordingly. In the multivariable analysis, patients commenced on statins had the
31
32 highest risk of receiving a first prescription of metformin in 6 years after exposure compared to the Control
33
34 group (HR: 3.31; 95% CI: 2.56-4.30elevated; P < 0.01). In contrast to existing research, **when compared to**
35
36 **patients on diclofenac**, patients on Antihypertensives AAC group have moderate risk of receiving their first
37
38 prescription of metformin in 6 years (HR: 2.32; 95% CI: 1.74-3.09; P < 0.01), and patients in the
39
40 Antihypertensives TB group had a slightly **elevated** risk (HR: 1.59; 95% CI: 1.15-2.20; P < 0.01) (Table 3).
41
42 Our analysis indicates a duration-response: The HR of developing new-onset diabetes was approximately
43
44 constant over the duration of the study as demonstrated by the plot for the cumulative hazard ratios for
45
46 the first metformin prescription in each study cohort (Figure 2), adjusting for age, sex, and ethnicity.
47
48

49 Subgroup analyses: Patient demographics were analysed to assess other characteristics of recipients of
50
51 first metformin prescription (Appendix 3). Cox regression model analysis revealed that females had a lower
52
53 risk than males (HR = 0.85, 95% CI: 0.72-1.00, p = 0.05), and there was no difference in risk between age
54
55 groups within our cohort age range. However, risks were increased with all other ethnicities when
56
57
58
59
60

1
2
3
4
5 compared to New Zealand European. Pacific Island and Asian ethnic group had the highest risk at HR 3.57
6
7 (95%CI: 2.63-4.85, P < 0.01) and HR 3.72 (95% CI: 3.00-4.62, P<0.01) respectively.
8

9
10 To assess whether those at risk of developing diabetes were prescribed higher doses of their prescribed
11 medications, the drug doses of their first prescribed indexed medications in 2005 among those prescribed
12 metformin were assessed. In the Statin group, 96.9% of patients were prescribed 40mg and less of both
13 simvastatin and atorvastatin. For patients in the Antihypertensives TB group, 78.8% of patients were on
14 beta blockers and 88% of those on thiazides were on 2.5mg of bendrofluazide. This indicates patients
15 commenced on metformin were prescribed conservative dosing of cardiovascular risk modifying drugs.
16
17

18
19 There were 743 patients who swapped study cohorts during the study period. Of these, 220 were from the
20 Diclofenac group, 206 from Antihypertensives TB group, 166 from Antihypertensives AAC group and 151
21 from Statin group (Appendix 4). Excluding these patients in a per-protocol analysis had little effect on the
22 hazard ratios compared to the intention to treat analysis (results of analysis available but not included),
23 which could indicate the effect is rare or that the exposure is steady.
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Discussion

38
39 Patients on any cardiovascular risk modifying drugs had a higher risk of new-onset diabetes compared to
40 patients receiving diclofenac. Patients receiving a first prescription for statins were at the highest risk of
41 subsequently developing clinically significant diabetes, with a risk three times that of those prescribed
42 diclofenac. Patients prescribed ACE inhibitors, ARBs or calcium channel blockers were the next highest risk,
43 being twice as likely to receive a metformin prescription, while those prescribed thiazides and beta-
44 blockers were only at slightly increased risk.
45
46
47
48
49
50
51

52
53 The association between new-onset diabetes, as estimated by first metformin prescriptions, and initiation
54 of statins found in this study is consistent with recent reports. However, the risk in this population was
55 lower (3.1%) than the 9% risk reported in meta-analyses.²³⁻²⁵ More recent publications have identified the
56 risks of new-onset diabetes with statin drug use ranging from 2.4% to 8.5%.²³⁻²⁶ In contrast to our study,
57 the diagnosis of diabetes in these other studies were identified by indicators such as disease classification
58
59
60

1
2
3
4
5 recording, or intermediate indicators such as laboratory investigations of HbA1c and fasting serum glucose
6
7 readings. This will draw in milder levels of hyperglycemia where lifestyle changes can still be the first line
8
9 of management and where laboratory threshold determines disease rates. This study is the first to identify
10
11 the incident rate of clinically significant diabetes in patients prescribed statins as indicated by the first
12
13 prescription of metformin in a non-research population. This is an outcome that matters to patients.

14
15
16 Our study is also the first to compare the risks of diabetes development in patients on statins against
17
18 patients on other cardiovascular risk modifying drugs who might also be considered to be 'high risk'.
19
20 Patients initiated on antihypertensive drugs were, like those prescribed statins, at greater risk of
21
22 developing diabetes compared to those on diclofenac. Our findings therefore allow an assessment of the
23
24 comparative risks of new-onset diabetes in patients with already higher risk on different classes of
25
26 antihypertensives. There may be several explanations for the differences seen. Firstly, it may be a true
27
28 association. Secondly, it may be that patients with risk factors for diabetes (such as obesity) are less likely
29
30 to be prescribed treatment with associated increased risk of diabetes.^{14,27} Hence, they are more likely to
31
32 receive prescriptions of ACEi or ARBs for management of hypertension due to a lesser known risk of
33
34 inducing diabetes. We also observed conservative dosing in patients on thiazides and beta-blockers, which
35
36 may attenuate the risk. Presence of metabolic syndrome risk factors also increased the risk of subsequent
37
38 glucose elevation, on as well as off statin use.²⁸ This study is not able to answer these questions, but raises
39
40 these for future research.

41
42
43 Since all data collected are electronic records, patient persistence with medication can be grossly assessed.
44
45 There were high rates of persistence with medications within the study groups, in particular to the
46
47 antihypertensives and the statins. Given only a total of 743 patients (2.3% of 2005 cohort) swapped into
48
49 different study groups during the study period, there were relatively clean groups for analyses of risks.

50
51
52 The development of clinically significant diabetes was estimated using a proxy measure, utilising the first
53
54 prescription of metformin. The validity of using routinely collected and electronically stored prescription
55
56 data for diagnosing diabetes has been previously demonstrated.^{15,29} The use of routinely collected data
57
58 also provides access to a complete national population based cohort. We were able to assess this cohort
59
60

1
2
3
4
5 longitudinally over a period of 6 years in a representative primary care population rather than a trial
6
7 population with tightly constrained entry criteria.

10 **Limitations**

11
12 Our study has several limitations. The nature of the electronic datasets available means it is not possible to
13
14 obtain other factors contributing to cardiovascular and diabetes risks to more precisely define subgroups
15
16 and allow direct comparison of the cohorts' baseline levels of risk of developing diabetes (e.g. body mass
17
18 index and family history). **These are major uncontrolled confounding and effect modifiers that cannot be**
19
20 **accounted for in this study.**

21
22
23 There is also the risk of misclassification. Metformin may also be prescribed for management of other
24
25 conditions such as polycystic ovary syndrome and extreme insulin resistance with acanthosis nigricans,
26
27 however this is likely to account for only a small proportion of prescriptions. With first prescription of
28
29 metformin, we have also excluded patients who present infrequently to their primary health care
30
31 providers for well-checks and routine follow up (missing new-onset diabetes) and those who may have
32
33 presented acutely with diabetic emergency (as they will be commenced on alternate hypoglycaemic
34
35 agents).

36
37
38 It is also uncertain as to how frequently these patients are tested for diabetes mellitus in the primary care
39
40 setting, as the electronic system is not currently linked to laboratory data. The study is also unable to
41
42 control for the duration of mild hyperglycaemia prior to commencement of metformin.

43
44
45 In this study, we have not distinguished between the various statin doses and formulations.

51 **Conclusions**

52
53 Patients initiating treatment with any of the index cardiovascular risk modifying drugs have some risk of
54
55 developing clinically significant new-onset diabetes compared to those prescribed diclofenac. However,
56
57 patients prescribed statins have the highest risk of new-onset diabetes, strengthening the recent signal
58
59 from current literature. Patients prescribed ACE inhibitors, angiotensin II receptor blockers and calcium
60
channel blockers were also at moderately increased risk, while patients prescribed thiazides and beta-

1
2
3
4
5 blockers only appeared to have a mildly increased risk. The effect seen carries an exposure duration-
6
7 response groups, and is also seen in patients prescribed relatively low doses of these drugs, which is
8
9 important information for prescribers. This provides additional information on the comparative safety of
10
11 these drugs in a real world setting in primary care, where the bulk of these prescriptions are likely to be
12
13 initiated. This is useful information for doctors and patients considering the balance of harms against the
14
15 potential for benefit of both statins and different cardiovascular risk modifying medications in different
16
17 populations.
18
19
20
21
22

23 **Further Research**

24
25 Whether there is an additive risk of inducing diabetes with combinations of different cardiovascular risk
26
27 modifying drugs is currently unknown, and an important area for research to inform decision making on
28
29 prescribing, given the prevalence of multi-morbidity and likely co-prescription. This is subject to a further
30
31 study. It is also unclear what effect this additional risk of diabetes will have on morbidity and mortality for
32
33 patients. Diabetes, as a diagnosis based on a measurement, is itself a source of morbidity and mortality
34
35 largely only as a risk factor for other disease, predominantly cardiovascular disease.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References


1. Taylor F HM, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. . *Cochrane Database of Systematic Reviews*. 2013(1):Art. No.: CD004816.
2. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. *Archives of internal medicine*. Jan 23 2012;172(2):144-152.
3. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. *QJM : monthly journal of the Association of Physicians*. Feb 2012;105(2):145-157.
4. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. *QJM : monthly journal of the Association of Physicians*. Feb 2011;104(2):109-124.
5. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. *Current opinion in lipidology*. Dec 2011;22(6):460-466.
6. Preiss D, Seshasai S, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A Meta-analysis. *JAMA*. 2011;305(4):2556-2564.
7. Sattar N, Preiss D, Murray H, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *The Lancet*. 2010;375:735-742.
8. Ridker P, Danielson E, Fonseca F, et al. Rosuvostatin to prevent vascular events in men and women with elevated CRP. *The New England Journal of Medicine*. 2008;359(21):2195-2207.
9. Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. *Atherosclerosis*. Jun 2009;204(2):483-490.
10. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. *Journal of the American College of Cardiology*. Mar 23 2010;55(12):1209-1216.

- 1
2
3
4
5 **11.** Cholesterol Treatment Trialists' collaborators. Efficacy and safety of cholesterol-lowering
6 treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of
7 statins. *Lancet*. 2005;366:1267-1278.
- 8
9
10
11 **12.** Movahed MR, Sattur S, Hashemzadeh M. Independent association between type 2 diabetes
12 mellitus and hypertension over a period of 10 years in a large inpatient population. *Clin Exp*
13 *Hypertens*. May 2010;32(3):198-201.
- 14
15
16
17 **13.** Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L. Adverse prognostic
18 significance of new diabetes in treated hypertensive subjects. *Hypertension*. 2004;43:963-969.
- 19
20
21
22 **14.** Dagenais GR AP, Bogaty P, Gerstein H, Lonn E, Yi Q, Yusuf S. Increased occurrence of diabetes in
23 people with ischemic cardiovascular disease and general and abdominal obesity. *Can J Cardiol*.
24 2003;19:1387-1391.
- 25
26
27
28
29
30 **15.** Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and
31 Wales: population based cohort study using QResearch database. *BMJ*. 2010;49:340.
- 32
33
34
35 **16.** Source: Ministry of Health, Pharmaceutical Collection.
- 36
37
38
39 **17.** Smith SM, Gong Y, Turner ST, et al. Blood pressure responses and metabolic effects of
40 hydrochlorothiazide and atenolol. *American journal of hypertension*. Mar 2012;25(3):359-365.
- 41
42
43
44 **18.** Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. *Journal of*
45 *Hypertension*. 2006;24:3-10.
- 46
47
48
49 **19.** Aksnes T, Reims H, Kjeldsen S, Mancia G. Antihypertensive Treatment and New Onset Diabetes
50 Mellitus. *Current Hypertension Reports*. 2005;7:298-303.
- 51
52
53
54 **20.** New Zealand Guidelines Group. New Zealand Primary Care Handbook 2012. 3rd ed. Wellington:
55 New Zealand Guidelines Group; 2012.
- 56
57
58
59 **21.** Dean AG SK, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version
60 2.3.1. www.OpenEpi.com, updated 2011/23/06, accessed 2012/10/23.
- 22.** Statistics New Zealand. <http://www.stats.govt.nz/infoshare>.

- 1
2
3
4
5 23. Wang K-L, Liu C-J, Chao T-F, et al. Statins, Risk of Diabetes, and Implications on Outcomes in the
6
7 General Population. *Journal of the American College of Cardiology*. 2012;60(14):1231-1238.
8
9
10 24. Rautio N, Jokelainen J, Oksa H. Do statins interfere with lifestyle intervention in the prevention of
11
12 diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. *BMJ Open*. 2012;2(5).
13
14 25. Ma T, Tien L, Fang C-L, Liou Y-S, Jong G-P. Statins and New-Onset Diabetes: A Retrospective
15
16 Longitudinal Cohort Study. *Clinical Therapeutics*. 2012;34(9):1977-1983.
17
18 26. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes
19
20 among patients treated with statins: population based study. *BMJ*. 2013:346.
21
22 27. Abdullah A, Stoelwinder J, Shortreed S, et al. The duration of obesity and the risk of type 2
23
24 diabetes. *Public health nutrition*. Jan 2011;14(1):119-126.
25
26
27 28. Golomb BA, Koperski S WH. Statins Raise Glucose Preferentially among Men who are Older and at
28
29 Greater Metabolic Risk. *Epidemiology and Prevention; Nutrition, Physical Activity and Metabolism*
30
31 *2012 Scientific Sessions*. San Diego, CA.2012.
32
33
34 29. Tu K. Diabetics can be identified in an electronic medical record using laboratory tests and
35
36 prescriptions. *J Epi*. 2011;64(4):431-435.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figures

Figure 1: Flow chart of cohort formation



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2: Hazard Ratio for first prescription of metformin in each year for different study groups



ew only

Tables

Table 1: Cohort Demographic

Characteristics	OVERALL	Diclofenac Group	Anti-hypertensives TB Group	Anti-hypertensives AAC Group	Statins Group
	% (n)	% (n)	% (n)	% (n)	% (n)
Recruited number of patients	100 (32086)	22.25 (7140)	17.98 (5769)	20.46 (6565)	39.31 (12612)
Sex					
<i>Male</i>	52.98 (16999)	49.69 (3548)	31.20 (1800)	49.52 (3251)	66.60 (8400)
<i>Female</i>	47.01 (15083)	50.29 (3591)	68.80 (3969)	50.46 (3313)	33.38 (4210)
<i>Unknown</i>	4	1	0	1	2
Age					
40-44	22.0 (7045)	33.8 (2415)	20.4 (1179)	19.1 (1255)	17.4 (2196)
45-49	22.7 (7289)	26.4 (1886)	22.4 (1295)	22.0 (1445)	21.1 (2663)
50-54	26.1 (8367)	21.1 (1509)	27.4 (1582)	27.3 (1794)	27.6 (3482)
55-59	29.2 (9385)	18.6 (1330)	29.7 (1713)	31.5 (2071)	33.9 (4271)
Ethnicity					
<i>NZ European[†]</i>	69.46 (22287)	61.3 (4377)	76.39 (4407)	69.23 (4545)	71.03 (8958)
<i>Maori</i>	7.05 (2261)	14.26 (1018)	5.91 (341)	7.75 (509)	3.12 (393)
<i>Pacific Island[*]</i>	3.48 (1116)	8.75 (625)	1.87 (108)	2.83 (186)	1.56 (197)
<i>Asian[#]</i>	5.31 (1703)	5.04 (360)	5.23 (302)	4.90 (322)	5.70 (719)
<i>Others[^]</i>	0.93 (298)	1.44 (103)	0.81 (47)	0.70 (46)	0.81 (102)
<i>Unknown[@]</i>	4421	657	564	957	2243

Table 2: Incidence rate for first prescription of metformin

Groups	Person-time	Number of new cases	Incidence rate cases per person year	Incidence rate cases per 1,000 person- years
Diclofenac	33190	84	0.00253	2.5
TB	30791	85	0.00276	2.8
AAC	35383	150	0.00424	4.2
Statin	70455	391	0.00555	5.5

Table 3: 6 year risk of first prescription of metformin in study groups compared to control group

			Univariable Analysis			Multivariable Analysis ^{1,2}		
	Total	Metformin (%)	HR	95% CI	P	HR	95% CI	P
Cohort								
Diclofenac	7140	84 (1.2)	1.00			1.00		
TB	5769	85 (1.5)	1.25	0.93-1.70	0.142	1.59	1.15-2.20	0.005
AAC	6565	150 (2.3)	1.95	1.50-2.55	<0.0001	2.32	1.74-3.09	<0.0001
Statin	12612	391 (3.1)	2.66	2.10-3.37	<0.0001	3.31	2.56-4.30	<0.0001

¹Cox Regression²Adjusting for: Age, sex, and ethnicity.

Appendices

Appendix 1: Summary of study analysis categories and drug lists

Groups	List of drugs	Sub group
Exclusion criteria	Insulin Neutral, Insulin Isophane, Insulin Isophane with Insulin	
Drugs (associated with increased risk of diabetes or are treatment for diabetes)	Neural, Insulin Lispro with Insulin Lispro Protamine, Insulin Glargine, Insulin Aspart, Insulin Glulisine, Insulin lispro, Acarbose, Glibenclamide, Gliclazide, Glipizide, Pioglitazone, Spironolactone, Cyproterone Acetate with Ethinyloestriodiol, Cyproterone acetate, Dexamethasone, Fludrocortisone Acetate, Hydrocortisone tablets, Methylprednisone, Prednisone Sodium Phosphate, Prednisone	
Diclofenac group	Diclofenac Sodium enteric coated tablets, Diclofenac Sodium Long Acting Tablets	
Anti-hypertensives TB Group	Atenolol, Carvedilol, Celiprolol, Labetalol, Metoprolol Succinate, Metoprolol Tartrate, Nadolol, Propranolol, Sotalol, Labetalol	BB
	Bendrofluazide, Chlorthalidone, Indapamide, Chlorothiazide	T
Anti-hypertensives AAC Group	Captopril, Cilazapril, Enalapril, Lisinopril, Quinapril	ACEi
	Candesartan, Losartan	ARB
	Amlodipine, Felodipine, Isradipine, Nifedipine, Diltiazem Hydrochloride, Verapamil Hydrochloride	CC
Statin Group	Atorvastatin, Pravastatin, Simvastatin	
Outcome Group	Metformin Hydrochloride	

Appendix 2: Number of patients persistent with medications in each cohort in every study year

Cohort\Years	2006	2007	2008	2009	2010	2011	%
TB	5769	5202	4834	4547	4339	4115	71.3%
AAC	6565	5958	5583	5227	4955	4654	70.9%
STATIN	12612	11752	11186	10757	10187	9593	76.1%

For peer review only

Appendix 3: 6 year risk of first prescription of metformin in different patient demographics.

					Univariable Analyses			Multivariable Analyses ^{1,2}		
	Total	%	Metformin	%	HR	95% CI	P	HR	95% CI	P
Sex										
M	16999	53.0%	409	1.3%	1.00	-	-	1.00	-	-
F	15083	47.0%	301	0.9%	0.83	0.71-0.96	0.01	0.85	0.72-1.00	0.05
Unknown	4	0.00%	0	0.0%	-	-	-	-	-	-
Age										
40-44	7045	22.0%	163	0.5%	1.00	-	-	1.00	-	-
45-49	7289	22.7%	156	0.5%	0.93	0.74-1.15	0.49	0.87	0.69-1.10	0.25
50-54	8367	26.1%	185	0.6%	0.96	0.77-1.18	0.67	0.88	0.70-1.11	0.27
55-59	9385	29.2%	206	0.6%	0.95	0.77-1.17	0.61	0.96	0.77-1.20	0.71
Ethnicity										
European	22287	69.5%	384	1.2%	1.00	-	-	1.00	-	-
Maori	2261	7.0%	66	0.2%	1.70	1.31-2.21	<0.01	2.23	1.71-2.91	<0.01
PI	1116	3.5%	49	0.2%	2.57	1.91-3.47	<0.01	3.57	2.63-4.85	<0.01
Asian	1703	5.3%	106	0.3%	3.69	2.98-4.57	<0.01	3.72	3.00-4.62	<0.01
Other	298	0.9%	11	0.0%	2.17	1.18-3.93	0.01	2.43	1.33-4.43	<0.01
Note:										
*European = NZ European, Other European, European NFD										
*Pacific Island = Cook Island, Fijian, Niuean, Samoan, Tokelauan, Tongan, Pacific Island, Other Pacific Island										
#Asian = Asian, Chinese, Other Asian, Indian, Southeast Asian										
^Others = African, Latin American/Hispanic, Middle Eastern, other, other ethnicity										

¹Cox Regression²Adjusting for: Age, sex, ethnicity, and study cohorts.

Appendix 4: 743 Patients who swapped study groups during study period

Group Swaps (From/To)	No Metformin	Metformin	Total Patient
Diclofenac Group	207	13	220
Antihypertensives TB Group	78	1	79
Antihypertensives AAC Group	56	1	57
Statin Group	73	11	84
Antihypertensives TB Group	198	8	206
Diclofenac Group	82	1	83
Antihypertensives AAC Group	98	6	104
Study Group	18	1	19
Antihypertensives AAC Group	163	3	166
Diclofenac Group	40	1	41
Antihypertensives TB Group	107	1	108
Statin Group	16	1	17
Statin Group	149	2	151
Diclofenac Group	104	1	105
Antihypertensives TB Group	24	0	24
Antihypertensives AAC Group	21	1	22
Total	717	26	743

Research Protocol

Project title: Drug Induced Diabetes: A Case of statins versus antihypertensives.

Date: April 2012

Principal investigator: Dr. Olivia Currie

Supervisor: Assoc. Professor Derelie Mangin

Project summary:

This is an observational prospective cohort study to assess whether the incidence of new onset diabetes is increased with the use of statin drugs; when compared to blood pressure drugs, and to a control group. The importance is indicated from previous experience with unwanted increased rate of cardiovascular events due to new onset diabetes with use of certain antihypertensives (1, 2). We will look at patients with first prescription of statin drugs and assess the proportion of users who develop diabetes in 5 years. We will compare this with groups of patients with first prescription of drugs for high blood pressure (high diabetes risk control group), and patients with none of these prescriptions but who have attendance for an ACC-related condition (normal control group). We will use clinical data held electronically on drug prescriptions and laboratory tests on the Pegasus Health Community ePrescription system.

Background:

In modern cardiovascular risk management, statin drugs are popular and beneficial adjuncts for prevention of primary and secondary cardiovascular events. All forms of pharmacotherapy have side effects. Common to statin drugs are increases in liver transaminases, muscle aches, cognition impairment and rhabdomyolysis, albeit rare. However, there is now new evidence to suggest that statin drugs could have drug class effect in causing diabetes in previously non-diabetic individuals (3).

Statin induced diabetes was first observed in the JUPITER trial (4) with relation to Rosuvostatin use in non-diabetic subjects. It was reported by physicians involved in the trial as a secondary outcome and concluded that more evidence is needed to confirm the observed effect. Following that, multiple meta-analyses correlated an overall 9% increased risk of diabetes with statin use with newer evidence showing association with Pravastatin and Rosuvostatin use (5-8). The meta-analyses, should be interpreted with caution as diabetes is often not the primary outcome in the trials analysed. Recent evidence indicates the risk of new onset diabetes with statin use could also be dose dependent (9). These drugs may still have an overall cardiovascular benefit nonetheless (10).

One of the difficulties in assessing the extent of the risk is that patients of higher cardiovascular risk also carry an increased risk of developing diabetes. In order that the risks and benefits of these drugs to be properly considered by patients and doctors, decisions whether to use them, it is very important to understand the extend of this risk in already high risk patients as development of diabetes further increases cardiovascular risk and carries its own morbidity, reducing lifespan and quality of life.

Objective

To assess comparative rates of diabetes development in patients in primary care population started on statin drugs; by comparing them with rates of diabetes development in patients also at high risk of cardiovascular disease started on blood pressure medications but not on statins, and with normal control group.

Methodology:

We will look at patients with first prescription of statin drugs and assess the proportion of users who develop diabetes in the subsequent 5 years. We will compare these rates in patients with first prescription of drugs for high blood pressure (high diabetes risk control group) and patients with none of these prescriptions (normal control group). Patients in the normal control group are those with without any of these prescriptions, and are recruited

1
2
3 from attendance for ACC-related conditions in the Canterbury region. We will use clinical
4 data held electronically on drug prescriptions and laboratory tests on the Pegasus Health
5 Community ePrescription system.
6

7 Study Design: Prospective cohort study using routinely collected data

8 Study population: Canterbury residents enrolled in Pegasus Health between ages 40 and 60,
9 who are commenced on either on statin drugs, or on antihypertensives (high risk control
10 group), or who have an ACC claim (low risk control group) in the years 2005 to 2007.

11 Exclusion: Patients who previously have diabetes, glucose intolerance, polycystic ovarian
12 syndrome, and those who are already on metformin, thiazides and corticosteroids (all
13 known to increase diabetes risk).
14

15 Other variables: From the clinical records where available the age, gender and sex; family
16 history of diabetes; body mass index; LDL level measured; blood glucose or HbA1c
17 measured; and smoking status. The purpose is to describe other cardiovascular risk factors,
18 if any, for groups of patients with prescription for statin drugs or drugs for high blood
19 pressure.
20

21 Follow up: Cohort will be followed up for 5 years.

22 Outcome measure: First prescription of Metformin, or HbA1c result indicating diabetes.

23 Analysis: Proportions compared between statin started, antihypertensives known to have
24 increased diabetes risk (thiazides and beta-blocker), antihypertensives known to have no
25 increased diabetic risk (ACE-inhibitors, ARBs, calcium channel blockers) and ACC control
26 group.
27

28 **Ethical considerations:**

29 No ethics committee is required by the National Ethics Advisory Committee, New Zealand as
30 stated in the *Ethical Guidelines for Observational Studies: Observational Research, Audits
31 and Related Activities, NEAC, December 2006*.

32 Pegasus Health has a method for anonymously electronically extracting and linking these
33 data. Patients are aware when they sign their enrolment form for Pegasus Health that their
34 data may be used anonymously for quality improvement. Data will be de-identified at the
35 point of extraction from the clinical record. Collection of such data will be stored in de-
36 identified manner. This study has been approved for support by the Pegasus Health
37 Research, Audit and Evaluation committee.
38

39 **References:**

- 40 1. Blackburn D, Wilson T. Antihypertensive medications and blood sugar: theories and implications. *Canadian Journal of*
41 *Cardiology*. 2006;22(3):229-33.
- 42 2. Aksnes T, Reims H, Kjeldsen S, Mancina G. Antihypertensive Treatment and New Onset Diabetes Mellitus. *Current Hypertension*
43 *Reports*. 2005;7:298-303.
- 44 3. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes
45 mellitus in postmenopausal women in the Women's Health Initiative. *Archives of internal medicine*. 2012;172(2):144-52. Epub
46 2012/01/11.
- 47 4. Ridker P, Danielson E, Fonseca F, Genest J, Gotto A, Kastelein J, et al. Rosuvostatin to prevent vascular events in men and
48 women with elevated CRP. *The New England Journal of Medicine*. 2008;359(21):2195-207.
- 49 5. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular
50 disease: an indirect comparison meta-analysis. *QJM : monthly journal of the Association of Physicians*. 2012;105(2):145-57.
51 Epub 2011/09/17.
- 52 6. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a
53 network meta-analysis of 170,255 patients from 76 randomized trials. *QJM : monthly journal of the Association of Physicians*.
54 2011;104(2):109-24. Epub 2010/10/12.
- 55 7. Sattar N, Preiss D, Murray H, Welsh P, Buckley B, de Craen A, et al. Statins and risk of incident diabetes: a collaborative meta-
56 analysis of randomised statin trials. *The Lancet*. 2010;375:735-42.
- 57 8. Cholesterol Treatment Trialists' collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis
58 of data from 90 056 participants in 14 randomised trials of statins. *Lancet*. 2005;366:1267-78.
- 59 9. Preiss D, Seshasai S, Welsh P, Murphy S, Ho J, Waters D, et al. Risk of incident diabetes with intensive-dose compared with
60 moderate-dose statin therapy: A Meta-analysis. *JAMA*. 2011;305(4):2556-64.
10. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. *Current opinion in lipidology*.
2011;22(6):460-6. Epub 2011/09/08.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Check
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	✓ (refer Manuscript Page 1)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	✓ (refer Manuscript Page 4)
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	✓ (refer Manuscript Page 6)
Objectives	3	State specific objectives, including any prespecified hypotheses	✓ (refer Manuscript Page 6)
Methods			
Study design	4	Present key elements of study design early in the paper	✓ (refer Manuscript Page 7)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	✓ (refer Manuscript Page 7)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	✓ (refer Manuscript Page 7-8)
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	✓ (refer Manuscript Page 8)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	✓ (refer Manuscript Page 7)
Bias	9	Describe any efforts to address potential sources of bias	Not applicable
Study size	10	Explain how the study size was arrived at	✓ (See Figure 1)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	✓ (refer Manuscript Page 8)

1				
2	Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	✓ (refer Manuscript Page 8)
3			(b) Describe any methods used to examine subgroups and interactions	✓ (refer Manuscript Page 8)
4			(c) Explain how missing data were addressed	Not applicable
5			(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	✓ (refer Manuscript Page 8)
6			<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
7		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy		
8		(e) Describe any sensitivity analyses	Not applicable	
9	Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	✓ (refer Manuscript Page 9)
10			(b) Give reasons for non-participation at each stage	
11			(c) Consider use of a flow diagram	✓ (Figure 1, page 17 Manuscript)
12	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	✓ (refer Manuscript Page 9, and table 1, page 19 Manuscript)
13			(b) Indicate number of participants with missing data for each variable of interest	✓
14			(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	✓ (refer Manuscript Page 9)
15	Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	✓ (refer Manuscript Page 9)
16			<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
17			<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
18	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	✓ (refer Manuscript Page 9, Figure 2 and Table 2)
19			(b) Report category boundaries when continuous variables were categorized	
20			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
21	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and	✓ (refer
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

		sensitivity analyses	Manuscript Page 10)
Discussion			
Key results	18	Summarise key results with reference to study objectives	✓ (refer Manuscript Page 11)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	✓ (refer Manuscript Page 12)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	✓ (refer Manuscript Page 13)
Generalisability	21	Discuss the generalisability (external validity) of the study results	✓ (refer Manuscript Page 13)
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	✓ (refer Manuscript Page 1)

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003475.R2
Article Type:	Research
Date Submitted by the Author:	15-Oct-2013
Complete List of Authors:	Currie, Olivia; Christchurch School of Medicine and Health Sciences, Public Health and General Practice Mangin, Dee; Christchurch School of Medicine and Health Sciences, Public Health and General Practice Williman, Jonathan; Christchurch School of Medicine and Health Sciences, Public Health and General Practice McKinnon-Gee, Bianca; Pegasus Health (Charitable) Limited, Bridgford, Paul; Pegasus Health (Charitable) Limited,
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Diabetes and endocrinology, Cardiovascular medicine
Keywords:	Audit < CARDIOLOGY, Lipid disorders < DIABETES & ENDOCRINOLOGY, PRIMARY CARE

SCHOLARONE™
Manuscripts

Only

MANUSCRIPT

Title Page

Title

The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.

Authors

Olivia Currie, MBChB, DCH¹, Dee Mangin, MBChB, DPH, FRNZCGP^{1,2}, Jonathan Williman, PhD, GradDipBiostat¹, Bianca McKinnon-Gee, BA, BSc, BCom³, Paul Bridgford, BSc³.

1. Department of Public Health and General Practice, University of Otago, P.O. Box 4345, Christchurch 8140. New Zealand.
2. Department of Family Medicine, McMaster University, 175 Longwood Road South, Suite 201A Hamilton ON L8P 0A1, Canada.
3. Pegasus Health (Charitable) Ltd. P O Box 741, Christchurch 8140. New Zealand

Corresponding author

Olivia Currie MBChB DCH, Department of Public Health and General Practice, University of Otago, P.O. Box 4345, Christchurch 8140. New Zealand. olivia.currie@otago.ac.nz

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPG products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

Word count

Abstract 296

Text 2942

Number of Tables

3

Number of figures

2

Key Words

Statins, diabetes, antihypertensives, metformin, primary care, electronic prescription.

Abbreviations

ACEi = angiotensin converting enzyme inhibitors

ARB = angiotensin II receptor blockers

CCB = calcium channel blockers

Study Groups:

Antihypertensives TB = thiazides and beta-blockers.

Antihypertensive AAC = angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers.

Abstract

Objective: Recent studies suggest statins increase the risk of subsequent diabetes with a clear dose response effect. However patients prescribed statins have a higher background risk of diabetes. This national cohort study aims to provide an estimate of the comparative risks for subsequent development of new-onset diabetes in adults prescribed statins, and those with already higher background risk on cardiovascular risk modifying drugs and a control drug.

Design: Longitudinal cohort study

Setting: Use of routinely collected data from a complete national primary care electronic prescription database in New Zealand.

Participants: 32,086 patients aged between 40 and 60 years in 2005 were eligible and assigned to four non-overlapping groups receiving their first prescription for:

1. diclofenac (healthy population) n=7140
2. antihypertensives thought likely to induce diabetes (thiazides and beta-blockers) n=5769
3. antihypertensives thought less likely to induce diabetes (ACEi, ARBs, CCB) n= 6565
4. statins n= 12 612

Outcome: Numbers of first metformin prescriptions were compared between these groups from 2006 to 2011.

Results: Patients prescribed statins have the highest risk of receiving a subsequent metformin prescription (HR: 3.31; 95% CI: 2.56 to 4.30; P < 0.01), followed by patients prescribed antihypertensives thought less likely to induce diabetes (HR: 2.32; 95% CI: 1.74 to 3.09; P < 0.01) and patients prescribed

1
2
3
4
5 antihypertensives thought more likely to induce diabetes (HR: 1.59; 95% CI: 1.15 to 2.20; P < 0.01) in the
6
7 subsequent 6 years of follow up, when compared to diclofenac.
8
9

10 Conclusions: These findings further support the link between statin use and new-onset diabetes; and
11 suggest the understanding of diabetes risk associated with different antihypertensive drug classes may
12 bear practice modification. This provides important information for future research, and for prescribers
13 and patients when considering the risks and benefits of different types of cardiovascular risk modifying
14
15
16
17
18
19
20 drugs.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Article focus:

- Estimates the comparative risks for subsequent development of new-onset diabetes in adults prescribed statins, other groups of cardiovascular risk modifying drugs indicating higher background risk and a control drug.

Key messages:

- Patients prescribed statins have the highest risk of receiving a subsequent metformin prescription (HR: 3.31; 95% CI: 2.56 to 4.30; $P < 0.01$) when compared to control drug.
- Patients on antihypertensives are also likely to receive their first metformin prescription when prescribed ACEi, ARB and CCB (HR: 2.32; 95% CI: 1.74 to 3.09; $P < 0.01$), and thiazides and beta-blockers (HR: 1.59; 95% CI: 1.15 to 2.20; $P < 0.01$) compared to control drug. However, this risk is not as high as those on statins.

Strengths:

- A national cohort study using electronic prescription database.
- First longitudinal study to compare incidence of subsequent diabetes between statins and antihypertensives with a control drug.
- First study to measure outcome by proxy of first metformin prescription as indication of significant diabetes development.

Limitations:

- Confounding factors like BMI, family history and socioeconomic status are not controlled for in this electronic database analysis. However, there is no indication that these factors are unevenly distributed between the different “high risk” study groups.
- There is a small risk of misclassification for prescription of metformin for other conditions such as polycystic ovary syndrome and extreme insulin resistance with acanthosis nigricans, but these are rare and are likely to only account for a small number of prescriptions.

For peer review only

Text

Introduction

Statins are widely used and have established benefits in the prevention of cardiovascular events.¹ However, recent studies suggested statins may also increase the risk of new-onset diabetes²⁻⁸, which in turn increases risk of cardiovascular events. One meta-analysis reported the odds to be 9% (OR: 1.09; 95% Confidence Interval (CI) 1.02 to 1.17)⁵, with other studies showing the association with pravastatin and rosuvostatin use.^{3,4,7,9-11} More recent data indicates the risk of new-onset diabetes with statin use could also be dose dependent, further supporting a causal link.⁶ Nevertheless, statins may still have an overall cardiovascular benefit.⁵

One of the difficulties in assessing the extent of this risk is that patients with higher cardiovascular risk prescribed statins also carry an increased baseline risk of developing diabetes because of similar risk factors.¹²⁻¹⁴ To understand the extent of the contributions of this increased baseline risk and the risk from the drugs themselves, we compared subsequent diabetes development in patients started on a statin with patients started on other drugs for cardiovascular risk management (antihypertensives) and patients at low baseline risk. We used a complete national prescribing dataset¹⁵ to create a population based cohort constructed of these three groups and compared the risk of subsequent development of clinically significant diabetes in each group.

Methods

Study design: Longitudinal cohort study using a national data set of de-identified routinely collected primary care electronic prescriptions of New Zealanders between ages 40 and 60, receiving first prescriptions of drugs studied (Appendix 1) in the year 2005.

Data source: Nationwide prescription data for the purpose of this study were sourced electronically from a complete national prescribing dataset, the New Zealand Health Information Service' (NZHIS) Pharmaceutical Collection.¹⁶ Community prescribing is electronic in primary care in New Zealand making this information accessible via NZHIS. Individual patients are assigned a unique identifier (NHI number) in

1
2
3
4
5 the New Zealand health system and this is attached to their prescriptions, allowing this to be the main
6
7 data key linkage tool. All NHIs were de-identified at the point of data extraction, and automatically
8
9 assigned a unique encrypted code.
10

11 Cohort construction: The cohort construction is illustrated in Figure 1 (Flow chart of cohort formation). The
12
13 cohort included patients aged 40-60 in the year 2005 without prior prescription of excluded drugs and
14
15 metformin (outcome drug) (Appendix 1), and all patients having received a prescription of at least one of
16
17 the drugs of interest between 2005 and 2011. These drugs were statins, antihypertensives, diclofenac
18
19 (comparator drug) or metformin (outcome drug). Diclofenac was chosen as the comparator drug to
20
21 represent low diabetic risk patients presenting to primary care services with musculoskeletal injuries.
22
23 Some antihypertensives are associated with subsequent development of diabetes. Thiazide diuretics (T)
24
25 and beta-blockers (BB) are most strongly associated with an increased risk,^{14,17-19} whereas little association
26
27 has been made with angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers
28
29 (ARB) and calcium channel blockers (CCB).^{18,19} Following the literature, those in the antihypertensive drug
30
31 group were further divided into “Antihypertensives TB” for antihypertensives thought likely to increase
32
33 diabetes risk (T and BB), and “Antihypertensives AAC” for antihypertensives thought less likely to do so
34
35 (ACEi, ARB and CCB). A total of 195,194 records listed at least one of the drugs in the drug groups under
36
37 study: Diclofenac, Antihypertensives TB, Antihypertensives AAC, and Statin groups. Patients belonging to
38
39 two study groups concurrently in 2005 were then excluded. Data were further examined and cleaned to
40
41 identify duplicate individuals, exclusion drugs and data entry error. This left 32,086 unique individuals to
42
43 form the 2005 study cohort with 7140, 5769, 6565 and 12,612 in Diclofenac, Antihypertensives TB,
44
45 Antihypertensives AAC, Statin groups respectively.
46
47
48
49
50
51

52 Exclusion: Patients who had a prescription for oral hypoglycaemics, insulin, oral corticosteroids (known to
53
54 increase the risk of diabetes), or any of the study group medications of interest (Appendix 1) prior to 2005.
55
56 The upper age limit was chosen to limit the inclusion of cardiovascular drugs prescribed for treatment of
57
58 other cardiovascular conditions (e.g. heart failure).
59
60

1
2
3
4
5 Exposure: New Zealand adults who received their first prescription of statins, antihypertensives, or
6
7 diclofenac in the calendar year 2005 without prior prescription of exclusion drugs and metformin.
8

9
10 Primary Outcome Measure: The proportion of patients receiving their first prescription of metformin in
11
12 the calendar years 2006-2011. Metformin is the recommended first line treatment for newly diagnosed
13
14 type 2 diabetes mellitus in New Zealand.²⁰
15

16
17 Analysis: Patient baseline demographics were summarised using simple descriptive statistics and
18
19 differences between cohorts were assessed using chi-square statistics calculated on OpenEpi online²¹.
20
21 Since these are routinely collected electronic records, loss to follow up cannot be measured directly, and
22
23 will be measured by proxy of medication persistence, death and emigration rate. Persistence with
24
25 medications was determined as having at least one prescription a year, and persons-years were calculated
26
27 based on this data. Death and emigration rate were calculated by direct age standardisation based on
28
29 information available on Statistics New Zealand life-tables to estimate loss to follow up for our cohorts.²²
30
31 Incidence rates and hazard ratios (HR) with 95% confidence intervals (95% CI) were calculated to compare
32
33 the risk of new-onset diabetes between Diclofenac group and the other three cohorts. HR were calculated
34
35 in SPSS 20.0 for Windows (SPSS Inc) using cox proportional hazards regression, and multivariable analysis
36
37 was used to adjust for differences in the demographic structure of the cohorts. All analyses were 2-sided.
38
39
40
41
42
43

44 **Results:**

45
46 Patient characteristics: The baseline characteristics of the cohorts are summarised in Table 1 (Cohort
47
48 demographic). The sex of the patients differed by groups with a higher proportion of females (68.8%, $\chi^2(1)$
49
50 = 447.86 , p < 0.001) in the Antihypertensives TB group, and of males (66.6%, $\chi^2(1) = 545.35$, p < 0.001) in
51
52 the statin group. The age of patients also differed across groups with patients receiving cardiovascular risk
53
54 modifying drugs tending to be older than those in the diclofenac group ($\chi^2(1) = 1016.39$, p < 0.001). New
55
56 Zealand European was the major ethnicity in all study groups. There were more Maori in the Diclofenac
57
58 group with only a few in the statin group ($\chi^2(1) = 301.86$, p < 0.001). These differences between groups are
59
60 adjusted for in the multivariable analysis.

1
2
3
4
5 Cohort characteristics and follow up: A total of 32,086 unique patients were eligible for analysis from the
6
7 recruitment: 7140 for the Diclofenac group, 5769 for Antihypertensives TB group, 6565 for
8
9 Antihypertensives AAC group, and 12,612 for the Statin group (Figure 1). Persistence with index
10
11 medications for each group was 38.4%, 71.3%, 70.9% and 76.1% respectively (Appendix 2). The persistence
12
13 within the control group was expectedly lower as diclofenac is not usually indicated for long term use. Loss
14
15 of follow up due to deaths and emigration is estimated to be less than 2% of those who were not
16
17 persistent with medications, assuming death and emigration rate were similar to the overall New Zealand
18
19 population within similar age groups during the study period.
20
21

22 Primary analysis: Primary outcome results indicated that between 2006 and 2011, 710 patients within the
23
24 four groups received their first prescription of metformin. This represents 1.2%, 1.5%, 2.3% and 3.1% of
25
26 those exposed to Diclofenac, Antihypertensives TB, Antihypertensives AAC and Statin groups respectively.
27
28 The incidence rates were 2.5, 2.8, 4.2 and 5.5 cases per 1,000 person years for first prescription of
29
30 metformin (Table 2) accordingly. In the multivariable analysis, patients commenced on statins had the
31
32 highest risk of receiving a first prescription of metformin in 6 years after exposure compared to the Control
33
34 group (HR: 3.31; 95% CI: 2.56-4.30; P < 0.01). In contrast to existing research, when compared to patients
35
36 on diclofenac, patients on Antihypertensives AAC group have moderate risk of receiving their first
37
38 prescription of metformin in 6 years (HR: 2.32; 95% CI: 1.74-3.09; P < 0.01), and patients in the
39
40 Antihypertensives TB group have slightly elevated risk (HR: 1.59; 95% CI: 1.15-2.20; P < 0.01) (Table 3). Our
41
42 analysis indicates a duration-response: The HR of developing new-onset diabetes was approximately
43
44 constant over the duration of the study as demonstrated by the plot for the cumulative hazard ratios for
45
46 the first metformin prescription in each study cohort (Figure 2), adjusting for age, sex, and ethnicity.
47
48

49 Subgroup analyses: Patient demographics were analysed to assess other characteristics of recipients of
50
51 first metformin prescription (Appendix 3). Cox regression model analysis revealed that females had a lower
52
53 risk than males (HR = 0.85, 95% CI: 0.72-1.00, p = 0.05), and there was no difference in risk between age
54
55 groups within our cohort age range. However, risks were increased with all other ethnicities when
56
57
58
59
60

1
2
3
4
5 compared to New Zealand European. Pacific Island and Asian ethnic group had the highest risk at HR 3.57
6
7 (95% CI: 2.63-4.85, $P < 0.01$) and HR 3.72 (95% CI: 3.00-4.62, $P < 0.01$) respectively.

8
9
10 To assess whether those at risk of developing diabetes were prescribed higher doses of their prescribed
11
12 medications, the drug doses of their first prescribed indexed medications in 2005 among those prescribed
13
14 metformin were assessed. In the Statin group, 96.9% of patients were prescribed 40mg and less of both
15
16 simvastatin and atorvastatin. For patients in the Antihypertensives TB group, 78.8% of patients were on
17
18 beta blockers and 88% of those on thiazides were on 2.5mg of bendrofluazide. This indicates patients
19
20 commenced on metformin were prescribed conservative doses of cardiovascular risk modifying drugs.

21
22
23 There were 743 patients who swapped study cohorts during the study period. Of these, 220 were from the
24
25 Diclofenac group, 206 from Antihypertensives TB group, 166 from Antihypertensives AAC group and 151
26
27 from Statin group (Appendix 4). Excluding these patients in a per-protocol analysis had little effect on the
28
29 hazard ratios compared to the intention to treat analysis (results of analysis available but not included),
30
31 which could indicate the effect is rare or that the exposure is steady.
32
33
34
35
36

37 Discussion

38
39 Patients on any cardiovascular risk modifying drugs had a higher risk of new-onset diabetes compared to
40
41 patients receiving diclofenac. Patients receiving first prescription for statins were at the highest risk of
42
43 subsequently developing clinically significant diabetes, with a risk three times that of those prescribed
44
45 diclofenac. Patients prescribed ACEi, ARBs or CCB were the next highest risk, being twice as likely to
46
47 receive a metformin prescription, while those prescribed thiazides and beta-blockers were only at slightly
48
49 increased risk.
50
51

52
53 The association between new-onset diabetes, as estimated by first metformin prescriptions, and initiation
54
55 of statins found in this study is consistent with recent reports. However, the risk in this population was
56
57 lower (3.1%) than the 9% risk reported in meta-analyses.²³⁻²⁵ More recent publications have identified the
58
59 risks of new-onset diabetes with statin drug use ranging from 2.4% to 8.5%.²³⁻²⁶ In contrast to our study,
60
the diagnosis of diabetes in these other studies were identified by indicators such as disease classification

1
2
3
4
5 recording, or intermediate indicators such as laboratory investigations of HbA1c and fasting serum glucose
6
7 readings. This will draw in milder levels of hyperglycemia where lifestyle changes can still be the first line
8
9 of management and where laboratory threshold determines disease rates. This study is the first to identify
10
11 the incident rate of clinically significant diabetes as indicated by the first prescription of metformin in a
12
13 non-research population. This is an outcome that matters to patients.
14
15

16
17 Our study is also the first to compare the risks of diabetes development in patients on statins against
18
19 patients on other cardiovascular risk modifying drugs who might also be considered to be “high risk”.
20
21 Patients initiated on antihypertensive drugs were, like those prescribed statins, at greater risk of
22
23 developing diabetes compared to those on diclofenac. Our findings therefore allow an assessment of the
24
25 comparative risks of new-onset diabetes in patients with already higher risk on different classes of
26
27 antihypertensives. There may be several explanations for the differences seen. Firstly, it may be a true
28
29 association. Secondly, patients already with risk factors for diabetes (such as obesity) are less likely to be
30
31 prescribed medications that will further increase this risk.^{14,27} Hence, they are more likely to receive
32
33 prescriptions of ACEi or ARBs for management of hypertension due to a lesser known risk of inducing
34
35 diabetes. We also observed conservative dosing in patients on thiazides and beta-blockers, which may
36
37 attenuate the risk. Finally, higher baseline risk factors (dyslipidaemia and hypertension) that leads to
38
39 prescription of the study drugs also increases the risk of subsequent glucose elevation, and this effect is
40
41 observed in patients on as well as off statin use.²⁸ Our study is not able to answer these questions, but
42
43 raises these for future research.
44
45
46
47

48
49 Since all data collected are electronic records, patient persistence with medication can be grossly assessed.
50
51 There were high rates of persistence with medications within the study groups, in particular for the
52
53 antihypertensives and statins. Given only a total of 743 patients (2.3% of 2005 cohort) swapped into
54
55 different study groups during the study period, these were relatively clean groups for analyses of risks.
56
57 The development of clinically significant diabetes was estimated using a proxy measure, utilising the first
58
59 prescription of metformin. The validity of using routinely collected and electronically stored prescription
60
data for diagnosing diabetes has been previously demonstrated.^{15,29} The use of routinely collected data

1
2
3
4
5 also provides access to a complete national population based cohort. We were able to assess this cohort
6
7 longitudinally over a period of 6 years in a representative primary care population rather than a trial
8
9 population with tightly constrained entry criteria.
10

11 **Limitations**

12
13 Our study has several limitations. The nature of the electronic datasets available means it is not possible to
14
15 obtain other factors contributing to cardiovascular and diabetes risks to more precisely define subgroups
16
17 and allow direct comparison of the cohorts' baseline levels of risk of developing diabetes (e.g. body mass
18
19 index and family history). These are major uncontrolled confounding and effect modifiers that cannot be
20
21 accounted for in this study.
22
23

24
25 There is also the risk of misclassification. Metformin may also be prescribed for management of other
26
27 conditions such as polycystic ovary syndrome and extreme insulin resistance with acanthosis nigricans,
28
29 however this is likely to account for only a small proportion of prescriptions. With first prescription of
30
31 metformin, we have also excluded patients who present infrequently to their primary health care
32
33 providers for well-checks and routine follow up (missing new-onset diabetes) and those who may have
34
35 presented acutely with diabetic emergency (as they will be commenced on alternate hypoglycaemic
36
37 agents).
38
39

40
41 It is also uncertain as to how frequently these patients are tested for diabetes mellitus in the primary care
42
43 setting, as the electronic system is not currently linked to laboratory data. The study is also unable to
44
45 control for the duration of mild hyperglycaemia prior to commencement of metformin.
46
47

48
49 In this study, we have not distinguished between the various statin doses and formulations.
50
51

52 **Conclusions**

53
54 Patients initiating treatment with any of the index cardiovascular risk modifying drugs have some risk of
55
56 developing clinically significant new-onset diabetes compared to those prescribed diclofenac. However,
57
58 patients prescribed statins have the highest risk of new-onset diabetes, strengthening the recent signal
59
60 from current literature. Patients prescribed ACEi, ARBs and CCB were also at moderately increased risk,

1
2
3
4
5 while patients prescribed thiazides and beta-blockers only appeared to have a mildly increased risk. The
6
7 effect seen carries an exposure and duration-response between groups, and is also seen in patients
8
9 prescribed relatively low doses of these drugs, which is important information for prescribers. This
10
11 provides additional information on the comparative safety of these drugs in a real world setting in primary
12
13 care, where the bulk of these prescriptions are likely to be initiated. This is useful information for doctors
14
15 and patients considering the balance of harms against the potential for benefit of both statins and
16
17 different cardiovascular risk modifying medications in different populations.
18
19
20
21
22

23 **Further Research**

24
25 Diabetes, as a diagnosis based on a measurement, is itself a source of morbidity and mortality largely as a
26
27 risk factor for other disease, predominantly cardiovascular disease. Whether there is an additive risk of
28
29 inducing diabetes with combinations of different cardiovascular risk modifying drugs is currently unknown,
30
31 and an important area for research to inform decision making on prescribing, given the prevalence of
32
33 multi-morbidity and likely co-prescription. This is subject to a further study. It is also unclear what effect
34
35 this additional risk of diabetes will have on morbidity and mortality for patients.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Prior Presentations

None

Ethics Application

As all data were de-identified by encryption, ethics approval was confirmed as not required by the National Ethics Advisory Committee, New Zealand as stated in the *Ethical Guidelines for Observational Studies: Observational Research, Audits and Related Activities, NEAC, December 2006* (Upper South B Regional Ethics Committee, Ethics ref: URB/12/EXP/022).

Acknowledgements

We thank the Canterbury Chair of General Practice Trust (Inc.) for the sponsoring the role of the General Practice Research Registrar for this project. We also thank the University of Otago, New Zealand for providing all computing softwares.

Conflict of Interest Statement

None

Prior Publication

None

Data Sharing

Technical appendix, statistical code, and dataset available from the corresponding author at Dryad repository, who will provide a permanent, citable and open access home for the dataset.

Contributorship

Olivia Currie, Dee Mangin, Bianca McKinnon-Gee and Paul Bridgford design the study. Bianca McKinnon-Gee ran the search for electronic prescription data according to study protocol. Olivia Currie designed data

1
2
3
4
5 collection tools, monitored data collection for the whole study, wrote the statistical analysis plan, cleaned
6
7 and analysed the data, and drafted and revised the paper. Olivia Currie and Jonathan Williman analysed
8
9 the data. Olivia Currie, Dee Mangin and Jonathan Williman revised the draft paper.
10
11
12
13
14
15
16
17
18

19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

References

1. Taylor F HM, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. . *Cochrane Database of Systematic Reviews*. 2013(1):Art. No.: CD004816.
2. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. *Archives of internal medicine*. Jan 23 2012;172(2):144-152.
3. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. *QJM : monthly journal of the Association of Physicians*. Feb 2012;105(2):145-157.
4. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. *QJM : monthly journal of the Association of Physicians*. Feb 2011;104(2):109-124.
5. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. *Current opinion in lipidology*. Dec 2011;22(6):460-466.
6. Preiss D, Seshasai S, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A Meta-analysis. *JAMA*. 2011;305(4):2556-2564.
7. Sattar N, Preiss D, Murray H, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *The Lancet*. 2010;375:735-742.

- 1
2
3
4
5 **8.** Ridker P, Danielson E, Fonseca F, et al. Rosuvostatin to prevent vascular events in men and women
6 with elevated CRP. *The New England Journal of Medicine*. 2008;359(21):2195-2207.
- 7
8
9
10 **9.** Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in
11 hypercholesterolemic patients. *Atherosclerosis*. Jun 2009;204(2):483-490.
- 12
13
14 **10.** Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and
15 increases ambient glycemia in hypercholesterolemic patients. *Journal of the American College of*
16 *Cardiology*. Mar 23 2010;55(12):1209-1216.
- 17
18
19
20
21 **11.** Cholesterol Treatment Trialists' collaborators. Efficacy and safety of cholesterol-lowering
22 treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of
23 statins. *Lancet*. 2005;366:1267-1278.
- 24
25
26
27
28 **12.** Movahed MR, Sattur S, Hashemzadeh M. Independent association between type 2 diabetes
29 mellitus and hypertension over a period of 10 years in a large inpatient population. *Clin Exp*
30 *Hypertens*. May 2010;32(3):198-201.
- 31
32
33
34
35 **13.** Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L. Adverse prognostic
36 significance of new diabetes in treated hypertensive subjects. *Hypertension*. 2004;43:963-969.
- 37
38
39
40
41 **14.** Dagenais GR AP, Bogaty P, Gerstein H, Lonn E, Yi Q, Yusuf S. Increased occurrence of diabetes in
42 people with ischemic cardiovascular disease and general and abdominal obesity. *Can J Cardiol*.
43 2003;19:1387-1391.
- 44
45
46
47
48 **15.** Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and
49 Wales: population based cohort study using QResearch database. *BMJ*. 2010;49:340.
- 50
51
52
53
54 **16.** Source: Ministry of Health, Pharmaceutical Collection.
- 55
56
57
58 **17.** Smith SM, Gong Y, Turner ST, et al. Blood pressure responses and metabolic effects of
59 hydrochlorothiazide and atenolol. *American journal of hypertension*. Mar 2012;25(3):359-365.
- 60
18. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. *Journal of*
Hypertension. 2006;24:3-10.

- 1
2
3
4
5 19. Aksnes T, Reims H, Kjeldsen S, Mancia G. Antihypertensive Treatment and New Onset Diabetes
6 Mellitus. *Current Hypertension Reports*. 2005;7:298-303.
- 7
8
9
10 20. New Zealand Guidelines Group. New Zealand Primary Care Handbook 2012. 3rd ed. Wellington:
11 New Zealand Guidelines Group; 2012.
- 12
13
14 21. Dean AG SK, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version
15 2.3.1. www.OpenEpi.com, updated 2011/23/06, accessed 2012/10/23.
- 16
17
18 22. Statistics New Zealand. <http://www.stats.govt.nz/infoshare>.
- 19
20
21 23. Wang K-L, Liu C-J, Chao T-F, et al. Statins, Risk of Diabetes, and Implications on Outcomes in the
22 General Population. *Journal of the American College of Cardiology*. 2012;60(14):1231-1238.
- 23
24
25 24. Rautio N, Jokelainen J, Oksa H. Do statins interfere with lifestyle intervention in the prevention of
26 diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. *BMJ Open*. 2012;2(5).
- 27
28
29 25. Ma T, Tien L, Fang C-L, Liou Y-S, Jong G-P. Statins and New-Onset Diabetes: A Retrospective
30 Longitudinal Cohort Study. *Clinical Therapeutics*. 2012;34(9):1977-1983.
- 31
32
33 26. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes
34 among patients treated with statins: population based study. *BMJ*. 2013:346.
- 35
36
37 27. Abdullah A, Stoelwinder J, Shortreed S, et al. The duration of obesity and the risk of type 2
38 diabetes. *Public health nutrition*. Jan 2011;14(1):119-126.
- 39
40
41 28. Golomb BA, Koperski S, White HL. Statins Raise Glucose Preferentially among Men who are Older
42 and at Greater Metabolic Risk. *Circulation* 2012;125:A055.
- 43
44
45 29. Tu K. Diabetics can be identified in an electronic medical record using laboratory tests and
46 prescriptions. *J Epi*. 2011;64(4):431-435.
- 47
48
49
50
51
52
53
54
55
56
57
58
59
60

MANUSCRIPT

Title Page

Title

The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.

Authors

Olivia Currie, MBChB, DCH¹, Dee Mangin, MBChB, DPH, FRNZCGP^{1,2}, Jonathan Williman, PhD, GradDipBiostat¹, Bianca McKinnon-Gee, BA, BSc, BCom³, Paul Bridgford, BSc³.

1. Department of Public Health and General Practice, University of Otago, P.O. Box 4345, Christchurch 8140. New Zealand.
2. Department of Family Medicine, McMaster University, 175 Longwood Road South, Suite 201A Hamilton ON L8P 0A1, Canada.
3. Pegasus Health (Charitable) Ltd. P O Box 741, Christchurch 8140. New Zealand

Corresponding author

Olivia Currie MBChB DCH, Department of Public Health and General Practice, University of Otago, P.O. Box 4345, Christchurch 8140. New Zealand. olivia.currie@otago.ac.nz

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPG products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

Word count

Abstract 296

Text 2942

Number of Tables

3

Number of figures

2

Key Words

Statins, diabetes, antihypertensives, metformin, primary care, electronic prescription.

Abbreviations

ACEi = angiotensin converting enzyme inhibitors

ARB = angiotensin II receptor blockers

CCB = calcium channel blockers

Study Groups:

Antihypertensives TB = thiazides and beta-blockers.

Antihypertensive AAC = angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers.

Abstract

Objective: Recent studies suggest statins increase the risk of subsequent diabetes with a clear dose response effect. However patients prescribed statins have a higher background risk of diabetes. This national cohort study aims to provide an estimate of the comparative risks for subsequent development of new-onset diabetes in adults prescribed statins, and those with already higher background risk on cardiovascular risk modifying drugs and a control drug.

Design: Longitudinal cohort study

Setting: Use of routinely collected data from a complete national primary care electronic prescription database in New Zealand.

Participants: 32,086 patients aged between 40 and 60 years in 2005 were eligible and assigned to four non-overlapping groups receiving their first prescription for:

1. diclofenac (healthy population) n=7140
2. antihypertensives thought likely to induce diabetes (thiazides and beta-blockers) n=5769
3. antihypertensives thought less likely to induce diabetes (ACEi, ARBs, CCB) n= 6565
4. statins n= 12 612

Outcome: Numbers of first metformin prescriptions were compared between these groups from 2006 to 2011.

Results: Patients prescribed statins have the highest risk of receiving a subsequent metformin prescription (HR: 3.31; 95% CI: 2.56 to 4.30; P < 0.01), followed by patients prescribed antihypertensives thought less likely to induce diabetes (HR: 2.32; 95% CI: 1.74 to 3.09; P < 0.01) and patients prescribed

1
2
3
4
5 antihypertensives thought more likely to induce diabetes (HR: 1.59; 95% CI: 1.15 to 2.20; P < 0.01) in the
6
7 subsequent 6 years of follow up, when compared to diclofenac.
8
9

10 Conclusions: These findings further support the link between statin use and new-onset diabetes; and
11 suggest the understanding of diabetes risk associated with different antihypertensive drug classes may
12 bear practice modification. This provides important information for future research, and for prescribers
13 and patients when considering the risks and benefits of different types of cardiovascular risk modifying
14
15
16
17
18
19
20 drugs.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Article focus:

- Estimates the comparative risks for subsequent development of new-onset diabetes in adults prescribed statins, other groups of cardiovascular risk modifying drugs indicating higher background risk and a control drug.

Key messages:

- Patients prescribed statins have the highest risk of receiving a subsequent metformin prescription (HR: 3.31; 95% CI: 2.56 to 4.30; $P < 0.01$) when compared to control drug.
- Patients on antihypertensives are also likely to receive their first metformin prescription when prescribed ACEi, ARB and CCB (HR: 2.32; 95% CI: 1.74 to 3.09; $P < 0.01$), and thiazides and beta-blockers (HR: 1.59; 95% CI: 1.15 to 2.20; $P < 0.01$) compared to control drug. However, this risk is not as high as those on statins.

Strengths:

- A national cohort study using electronic prescription database.
- First longitudinal study to compare incidence of subsequent diabetes between statins and antihypertensives with a control drug.
- First study to measure outcome by proxy of first metformin prescription as indication of significant diabetes development.

Limitations:

- Confounding factors like BMI, family history and socioeconomic status are not controlled for in this electronic database analysis. However, there is no indication that these factors are unevenly distributed between the different “high risk” study groups.
- There is a small risk of misclassification for prescription of metformin for other conditions such as polycystic ovary syndrome and extreme insulin resistance with acanthosis nigricans, but these are rare and are likely to only account for a small number of prescriptions.

For peer review only

Text

Introduction

Statins are widely used and have established benefits in the prevention of cardiovascular events.¹ However, recent studies suggested statins may also increase the risk of new-onset diabetes²⁻⁸, which in turn increases risk of cardiovascular events. One meta-analysis reported the odds to be 9% (OR: 1.09; 95% Confidence Interval (CI) 1.02 to 1.17)⁵, with other studies showing the association with pravastatin and rosuvostatin use.^{3,4,7,9-11} More recent data indicates the risk of new-onset diabetes with statin use could also be dose dependent, further supporting a causal link.⁶ Nevertheless, statins may still have an overall cardiovascular benefit.⁵

One of the difficulties in assessing the extent of this risk is that patients with higher cardiovascular risk prescribed statins also carry an increased baseline risk of developing diabetes because of similar risk factors.¹²⁻¹⁴ To understand the extent of the contributions of this increased baseline risk and the risk from the drugs themselves, we compared subsequent diabetes development in patients started on a statin with patients started on other drugs for cardiovascular risk management (antihypertensives) and patients at low baseline risk. We used a complete national prescribing dataset¹⁵ to create a population based cohort constructed of these three groups and compared the risk of subsequent development of clinically significant diabetes in each group.

Methods

Study design: Longitudinal cohort study using a national data set of de-identified routinely collected primary care electronic prescriptions of New Zealanders between ages 40 and 60, receiving first prescriptions of drugs studied (Appendix 1) in the year 2005.

Data source: Nationwide prescription data for the purpose of this study were sourced electronically from a complete national prescribing dataset, the New Zealand Health Information Service' (NZHIS) Pharmaceutical Collection.¹⁶ Community prescribing is electronic in primary care in New Zealand making this information accessible via NZHIS. Individual patients are assigned a unique identifier (NHI number) in

1
2
3
4
5 the New Zealand health system and this is attached to their prescriptions, allowing this to be the main
6
7 data key linkage tool. All NHIs were de-identified at the point of data extraction, and automatically
8
9 assigned a unique encrypted code.
10

11 Cohort construction: The cohort construction is illustrated in Figure 1 (Flow chart of cohort formation). The
12
13 cohort included patients aged 40-60 in the year 2005 without prior prescription of excluded drugs and
14
15 metformin (outcome drug) (Appendix 1), and all patients having received a prescription of at least one of
16
17 the drugs of interest between 2005 and 2011. These drugs were statins, antihypertensives, diclofenac
18
19 (comparator drug) or metformin (outcome drug). Diclofenac was chosen as the comparator drug to
20
21 represent low diabetic risk patients presenting to primary care services with musculoskeletal injuries.
22
23 Some antihypertensives are associated with subsequent development of diabetes. Thiazide diuretics (T)
24
25 and beta-blockers (BB) are most strongly associated with an increased risk,^{14,17-19} whereas little association
26
27 has been made with angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers
28
29 (ARB) and calcium channel blockers (CCB).^{18,19} Following the literature, those in the antihypertensive drug
30
31 group were further divided into “Antihypertensives TB” for antihypertensives thought likely to increase
32
33 diabetes risk (T and BB), and “Antihypertensives AAC” for antihypertensives thought less likely to do so
34
35 (ACEi, ARB and CCB). A total of 195,194 records listed at least one of the drugs in the drug groups under
36
37 study: Diclofenac, Antihypertensives TB, Antihypertensives AAC, and Statin groups. Patients belonging to
38
39 two study groups concurrently in 2005 were then excluded. Data were further examined and cleaned to
40
41 identify duplicate individuals, exclusion drugs and data entry error. This left 32,086 unique individuals to
42
43 form the 2005 study cohort with 7140, 5769, 6565 and 12,612 in Diclofenac, Antihypertensives TB,
44
45 Antihypertensives AAC, Statin groups respectively.
46
47
48
49
50
51

52 Exclusion: Patients who had a prescription for oral hypoglycaemics, insulin, oral corticosteroids (known to
53
54 increase the risk of diabetes), or any of the study group medications of interest (Appendix 1) prior to 2005.
55
56 The upper age limit was chosen to limit the inclusion of cardiovascular drugs prescribed for treatment of
57
58 other cardiovascular conditions (e.g. heart failure).
59
60

1
2
3
4
5 Exposure: New Zealand adults who received their first prescription of statins, antihypertensives, or
6
7 diclofenac in the calendar year 2005 without prior prescription of exclusion drugs and metformin.

8
9
10 Primary Outcome Measure: The proportion of patients receiving their first prescription of metformin in
11
12 the calendar years 2006-2011. Metformin is the recommended first line treatment for newly diagnosed
13
14 type 2 diabetes mellitus in New Zealand.²⁰

15
16 Analysis: Patient baseline demographics were summarised using simple descriptive statistics and
17
18 differences between cohorts were assessed using chi-square statistics calculated on OpenEpi online²¹.
19
20 Since these are routinely collected electronic records, loss to follow up cannot be measured directly, and
21
22 will be measured by proxy of medication persistence, death and emigration rate. Persistence with
23
24 medications was determined as having at least one prescription a year, and persons-years were calculated
25
26 based on this data. Death and emigration rate were calculated by direct age standardisation based on
27
28 information available on Statistics New Zealand life-tables to estimate loss to follow up for our cohorts.²²
29
30 Incidence rates and hazard ratios (HR) with 95% confidence intervals (95% CI) were calculated to compare
31
32 the risk of new-onset diabetes between Diclofenac group and the other three cohorts. HR were calculated
33
34 in SPSS 20.0 for Windows (SPSS Inc) using cox proportional hazards regression, and multivariable analysis
35
36 was used to adjust for differences in the demographic structure of the cohorts. All analyses were 2-sided.
37
38
39
40
41
42
43

44 **Results:**

45
46 Patient characteristics: The baseline characteristics of the cohorts are summarised in Table 1 (Cohort
47
48 demographic). The sex of the patients differed by groups with a higher proportion of females (68.8%, $\chi^2(1)$
49
50 = 447.86 , p < 0.001) in the Antihypertensives TB group, and of males (66.6%, $\chi^2(1) = 545.35$, p < 0.001) in
51
52 the statin group. The age of patients also differed across groups with patients receiving cardiovascular risk
53
54 modifying drugs tending to be older than those in the diclofenac group ($\chi^2(1) = 1016.39$, p < 0.001). New
55
56 Zealand European was the major ethnicity in all study groups. There were more Maori in the Diclofenac
57
58 group with only a few in the statin group ($\chi^2(1) = 301.86$, p < 0.001). These differences between groups are
59
60 adjusted for in the multivariable analysis.

1
2
3
4
5 Cohort characteristics and follow up: A total of 32,086 unique patients were eligible for analysis from the
6
7 recruitment: 7140 for the Diclofenac group, 5769 for Antihypertensives TB group, 6565 for
8
9 Antihypertensives AAC group, and 12,612 for the Statin group (Figure 1). Persistence with index
10
11 medications for each group was 38.4%, 71.3%, 70.9% and 76.1% respectively (Appendix 2). The persistence
12
13 within the control group was expectedly lower as diclofenac is not usually indicated for long term use. Loss
14
15 of follow up due to deaths and emigration is estimated to be less than 2% of those who were not
16
17 persistent with medications, assuming death and emigration rate were similar to the overall New Zealand
18
19 population within similar age groups during the study period.
20
21

22 Primary analysis: Primary outcome results indicated that between 2006 and 2011, 710 patients within the
23
24 four groups received their first prescription of metformin. This represents 1.2%, 1.5%, 2.3% and 3.1% of
25
26 those exposed to Diclofenac, Antihypertensives TB, Antihypertensives AAC and Statin groups respectively.
27
28 The incidence rates were 2.5, 2.8, 4.2 and 5.5 cases per 1,000 person years for first prescription of
29
30 metformin (Table 2) accordingly. In the multivariable analysis, patients commenced on statins had the
31
32 highest risk of receiving a first prescription of metformin in 6 years after exposure compared to the Control
33
34 group (HR: 3.31; 95% CI: 2.56-4.30; P < 0.01). In contrast to existing research, when compared to patients
35
36 on diclofenac, patients on Antihypertensives AAC group have moderate risk of receiving their first
37
38 prescription of metformin in 6 years (HR: 2.32; 95% CI: 1.74-3.09; P < 0.01), and patients in the
39
40 Antihypertensives TB group have slightly elevated risk (HR: 1.59; 95% CI: 1.15-2.20; P < 0.01) (Table 3). Our
41
42 analysis indicates a duration-response: The HR of developing new-onset diabetes was approximately
43
44 constant over the duration of the study as demonstrated by the plot for the cumulative hazard ratios for
45
46 the first metformin prescription in each study cohort (Figure 2), adjusting for age, sex, and ethnicity.
47
48

49 Subgroup analyses: Patient demographics were analysed to assess other characteristics of recipients of
50
51 first metformin prescription (Appendix 3). Cox regression model analysis revealed that females had a lower
52
53 risk than males (HR = 0.85, 95% CI: 0.72-1.00, p = 0.05), and there was no difference in risk between age
54
55 groups within our cohort age range. However, risks were increased with all other ethnicities when
56
57
58
59
60

1
2
3
4
5 compared to New Zealand European. Pacific Island and Asian ethnic group had the highest risk at HR 3.57
6
7 (95% CI: 2.63-4.85, $P < 0.01$) and HR 3.72 (95% CI: 3.00-4.62, $P < 0.01$) respectively.

8
9
10 To assess whether those at risk of developing diabetes were prescribed higher doses of their prescribed
11
12 medications, the drug doses of their first prescribed indexed medications in 2005 among those prescribed
13
14 metformin were assessed. In the Statin group, 96.9% of patients were prescribed 40mg and less of both
15
16 simvastatin and atorvastatin. For patients in the Antihypertensives TB group, 78.8% of patients were on
17
18 beta blockers and 88% of those on thiazides were on 2.5mg of bendrofluazide. This indicates patients
19
20 commenced on metformin were prescribed conservative doses of cardiovascular risk modifying drugs.

21
22
23 There were 743 patients who swapped study cohorts during the study period. Of these, 220 were from the
24
25 Diclofenac group, 206 from Antihypertensives TB group, 166 from Antihypertensives AAC group and 151
26
27 from Statin group (Appendix 4). Excluding these patients in a per-protocol analysis had little effect on the
28
29 hazard ratios compared to the intention to treat analysis (results of analysis available but not included),
30
31 which could indicate the effect is rare or that the exposure is steady.
32
33
34
35
36

37 Discussion

38
39 Patients on any cardiovascular risk modifying drugs had a higher risk of new-onset diabetes compared to
40
41 patients receiving diclofenac. Patients receiving first prescription for statins were at the highest risk of
42
43 subsequently developing clinically significant diabetes, with a risk three times that of those prescribed
44
45 diclofenac. Patients prescribed ACEi, ARBs or CCB were the next highest risk, being twice as likely to
46
47 receive a metformin prescription, while those prescribed thiazides and beta-blockers were only at slightly
48
49 increased risk.
50
51

52
53 The association between new-onset diabetes, as estimated by first metformin prescriptions, and initiation
54
55 of statins found in this study is consistent with recent reports. However, the risk in this population was
56
57 lower (3.1%) than the 9% risk reported in meta-analyses.²³⁻²⁵ More recent publications have identified the
58
59 risks of new-onset diabetes with statin drug use ranging from 2.4% to 8.5%.²³⁻²⁶ In contrast to our study,
60
the diagnosis of diabetes in these other studies were identified by indicators such as disease classification

1
2
3
4
5 recording, or intermediate indicators such as laboratory investigations of HbA1c and fasting serum glucose
6
7 readings. This will draw in milder levels of hyperglycemia where lifestyle changes can still be the first line
8
9 of management and where laboratory threshold determines disease rates. This study is the first to identify
10
11 the incident rate of clinically significant diabetes as indicated by the first prescription of metformin in a
12
13 non-research population. This is an outcome that matters to patients.

14
15
16 Our study is also the first to compare the risks of diabetes development in patients on statins against
17
18 patients on other cardiovascular risk modifying drugs who might also be considered to be “high risk”.
19
20 Patients initiated on antihypertensive drugs were, like those prescribed statins, at greater risk of
21
22 developing diabetes compared to those on diclofenac. Our findings therefore allow an assessment of the
23
24 comparative risks of new-onset diabetes in patients with already higher risk on different classes of
25
26 antihypertensives. There may be several explanations for the differences seen. Firstly, it may be a true
27
28 association. Secondly, patients already with risk factors for diabetes (such as obesity) are less likely to be
29
30 prescribed medications that will further increase this risk.^{14,27} Hence, they are more likely to receive
31
32 prescriptions of ACEi or ARBs for management of hypertension due to a lesser known risk of inducing
33
34 diabetes. We also observed conservative dosing in patients on thiazides and beta-blockers, which may
35
36 attenuate the risk. Finally, higher baseline risk factors (dyslipidaemia and hypertension) that leads to
37
38 prescription of the study drugs also increases the risk of subsequent glucose elevation, and this effect is
39
40 observed in patients on as well as off statin use.²⁸ Our study is not able to answer these questions, but
41
42 raises these for future research.

43
44
45 Since all data collected are electronic records, patient persistence with medication can be grossly assessed.
46
47 There were high rates of persistence with medications within the study groups, in particular for the
48
49 antihypertensives and statins. Given only a total of 743 patients (2.3% of 2005 cohort) swapped into
50
51 different study groups during the study period, these were relatively clean groups for analyses of risks.
52
53 The development of clinically significant diabetes was estimated using a proxy measure, utilising the first
54
55 prescription of metformin. The validity of using routinely collected and electronically stored prescription
56
57 data for diagnosing diabetes has been previously demonstrated.^{15,29} The use of routinely collected data
58
59
60

1
2
3
4
5 also provides access to a complete national population based cohort. We were able to assess this cohort
6
7 longitudinally over a period of 6 years in a representative primary care population rather than a trial
8
9 population with tightly constrained entry criteria.
10

11 **Limitations**

12
13 Our study has several limitations. The nature of the electronic datasets available means it is not possible to
14
15 obtain other factors contributing to cardiovascular and diabetes risks to more precisely define subgroups
16
17 and allow direct comparison of the cohorts' baseline levels of risk of developing diabetes (e.g. body mass
18
19 index and family history). These are major uncontrolled confounding and effect modifiers that cannot be
20
21 accounted for in this study.
22
23

24
25 There is also the risk of misclassification. Metformin may also be prescribed for management of other
26
27 conditions such as polycystic ovary syndrome and extreme insulin resistance with acanthosis nigricans,
28
29 however this is likely to account for only a small proportion of prescriptions. With first prescription of
30
31 metformin, we have also excluded patients who present infrequently to their primary health care
32
33 providers for well-checks and routine follow up (missing new-onset diabetes) and those who may have
34
35 presented acutely with diabetic emergency (as they will be commenced on alternate hypoglycaemic
36
37 agents).
38
39

40
41 It is also uncertain as to how frequently these patients are tested for diabetes mellitus in the primary care
42
43 setting, as the electronic system is not currently linked to laboratory data. The study is also unable to
44
45 control for the duration of mild hyperglycaemia prior to commencement of metformin.
46
47

48
49 In this study, we have not distinguished between the various statin doses and formulations.
50
51

52 **Conclusions**

53
54 Patients initiating treatment with any of the index cardiovascular risk modifying drugs have some risk of
55
56 developing clinically significant new-onset diabetes compared to those prescribed diclofenac. However,
57
58 patients prescribed statins have the highest risk of new-onset diabetes, strengthening the recent signal
59
60 from current literature. Patients prescribed ACEi, ARBs and CCB were also at moderately increased risk,

1
2
3
4
5 while patients prescribed thiazides and beta-blockers only appeared to have a mildly increased risk. The
6
7 effect seen carries an exposure and duration-response between groups, and is also seen in patients
8
9 prescribed relatively low doses of these drugs, which is important information for prescribers. This
10
11 provides additional information on the comparative safety of these drugs in a real world setting in primary
12
13 care, where the bulk of these prescriptions are likely to be initiated. This is useful information for doctors
14
15 and patients considering the balance of harms against the potential for benefit of both statins and
16
17 different cardiovascular risk modifying medications in different populations.
18
19
20
21
22

23 **Further Research**

24
25 Diabetes, as a diagnosis based on a measurement, is itself a source of morbidity and mortality largely as a
26
27 risk factor for other disease, predominantly cardiovascular disease. Whether there is an additive risk of
28
29 inducing diabetes with combinations of different cardiovascular risk modifying drugs is currently unknown,
30
31 and an important area for research to inform decision making on prescribing, given the prevalence of
32
33 multi-morbidity and likely co-prescription. This is subject to a further study. It is also unclear what effect
34
35 this additional risk of diabetes will have on morbidity and mortality for patients.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Prior Presentations

None

Ethics Application

As all data were de-identified by encryption, ethics approval was confirmed as not required by the National Ethics Advisory Committee, New Zealand as stated in the *Ethical Guidelines for Observational Studies: Observational Research, Audits and Related Activities, NEAC, December 2006* (Upper South B Regional Ethics Committee, Ethics ref: URB/12/EXP/022).

Acknowledgements

We thank the Canterbury Chair of General Practice Trust (Inc.) for the sponsoring the role of the General Practice Research Registrar for this project. We also thank the University of Otago, New Zealand for providing all computing softwares.

Conflict of Interest Statement

None

Prior Publication

None

Data Sharing

Technical appendix, statistical code, and dataset available from the corresponding author at Dryad repository, who will provide a permanent, citable and open access home for the dataset.

Contributorship

Olivia Currie, Dee Mangin, Bianca McKinnon-Gee and Paul Bridgford design the study. Bianca McKinnon-Gee ran the search for electronic prescription data according to study protocol. Olivia Currie designed data

1
2
3
4
5 collection tools, monitored data collection for the whole study, wrote the statistical analysis plan, cleaned
6
7 and analysed the data, and drafted and revised the paper. Olivia Currie and Jonathan Williman analysed
8
9 the data. Olivia Currie, Dee Mangin and Jonathan Williman revised the draft paper.
10
11
12
13
14
15
16
17
18

19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

References

1. Taylor F HM, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. . *Cochrane Database of Systematic Reviews*. 2013(1):Art. No.: CD004816.
2. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. *Archives of internal medicine*. Jan 23 2012;172(2):144-152.
3. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. *QJM : monthly journal of the Association of Physicians*. Feb 2012;105(2):145-157.
4. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. *QJM : monthly journal of the Association of Physicians*. Feb 2011;104(2):109-124.
5. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. *Current opinion in lipidology*. Dec 2011;22(6):460-466.
6. Preiss D, Seshasai S, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A Meta-analysis. *JAMA*. 2011;305(4):2556-2564.
7. Sattar N, Preiss D, Murray H, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *The Lancet*. 2010;375:735-742.

- 1
2
3
4
5 **8.** Ridker P, Danielson E, Fonseca F, et al. Rosuvostatin to prevent vascular events in men and women
6 with elevated CRP. *The New England Journal of Medicine*. 2008;359(21):2195-2207.
7
- 8
9 **9.** Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in
10 hypercholesterolemic patients. *Atherosclerosis*. Jun 2009;204(2):483-490.
11
- 12
13 **10.** Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and
14 increases ambient glycemia in hypercholesterolemic patients. *Journal of the American College of*
15 *Cardiology*. Mar 23 2010;55(12):1209-1216.
16
- 17
18 **11.** Cholesterol Treatment Trialists' collaborators. Efficacy and safety of cholesterol-lowering
19 treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of
20 statins. *Lancet*. 2005;366:1267-1278.
21
- 22
23 **12.** Movahed MR, Sattur S, Hashemzadeh M. Independent association between type 2 diabetes
24 mellitus and hypertension over a period of 10 years in a large inpatient population. *Clin Exp*
25 *Hypertens*. May 2010;32(3):198-201.
26
- 27
28 **13.** Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L. Adverse prognostic
29 significance of new diabetes in treated hypertensive subjects. *Hypertension*. 2004;43:963-969.
30
- 31
32 **14.** Dagenais GR AP, Bogaty P, Gerstein H, Lonn E, Yi Q, Yusuf S. Increased occurrence of diabetes in
33 people with ischemic cardiovascular disease and general and abdominal obesity. *Can J Cardiol*.
34 2003;19:1387-1391.
35
- 36
37 **15.** Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and
38 Wales: population based cohort study using QResearch database. *BMJ*. 2010;49:340.
39
- 40
41 **16.** Source: Ministry of Health, Pharmaceutical Collection.
42
- 43
44 **17.** Smith SM, Gong Y, Turner ST, et al. Blood pressure responses and metabolic effects of
45 hydrochlorothiazide and atenolol. *American journal of hypertension*. Mar 2012;25(3):359-365.
46
- 47
48 **18.** Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. *Journal of*
49 *Hypertension*. 2006;24:3-10.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5 19. Aksnes T, Reims H, Kjeldsen S, Mancia G. Antihypertensive Treatment and New Onset Diabetes
6 Mellitus. *Current Hypertension Reports*. 2005;7:298-303.
- 7
8
9
10 20. New Zealand Guidelines Group. New Zealand Primary Care Handbook 2012. 3rd ed. Wellington:
11 New Zealand Guidelines Group; 2012.
- 12
13
14 21. Dean AG SK, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version
15 2.3.1. www.OpenEpi.com, updated 2011/23/06, accessed 2012/10/23.
- 16
17
18 22. Statistics New Zealand. <http://www.stats.govt.nz/infoshare>.
- 19
20
21 23. Wang K-L, Liu C-J, Chao T-F, et al. Statins, Risk of Diabetes, and Implications on Outcomes in the
22 General Population. *Journal of the American College of Cardiology*. 2012;60(14):1231-1238.
- 23
24
25 24. Rautio N, Jokelainen J, Oksa H. Do statins interfere with lifestyle intervention in the prevention of
26 diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. *BMJ Open*. 2012;2(5).
- 27
28
29 25. Ma T, Tien L, Fang C-L, Liou Y-S, Jong G-P. Statins and New-Onset Diabetes: A Retrospective
30 Longitudinal Cohort Study. *Clinical Therapeutics*. 2012;34(9):1977-1983.
- 31
32
33 26. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes
34 among patients treated with statins: population based study. *BMJ*. 2013:346.
- 35
36
37 27. Abdullah A, Stoelwinder J, Shortreed S, et al. The duration of obesity and the risk of type 2
38 diabetes. *Public health nutrition*. Jan 2011;14(1):119-126.
- 39
40
41 28. Golomb BA, Koperski S, White HL. Statins Raise Glucose Preferentially among Men who are Older
42 and at Greater Metabolic Risk. *Circulation* 2012;125:A055.
- 43
44
45 29. Tu K. Diabetics can be identified in an electronic medical record using laboratory tests and
46 prescriptions. *J Epi*. 2011;64(4):431-435.
- 47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figures

Figure 1: Flow chart of cohort formation





Figure 2: Hazard Ratio for first prescription of metformin in each year for different study groups



ew only

Tables

Table 1: Cohort Demographic

Characteristics	OVERALL	Diclofenac Group	Anti-hypertensives TB Group	Anti-hypertensives AAC Group	Statins Group
	% (n)	% (n)	% (n)	% (n)	% (n)
Recruited number of patients	100 (32086)	22.25 (7140)	17.98 (5769)	20.46 (6565)	39.31 (12612)
Sex					
<i>Male</i>	52.98 (16999)	49.69 (3548)	31.20 (1800)	49.52 (3251)	66.60 (8400)
<i>Female</i>	47.01 (15083)	50.29 (3591)	68.80 (3969)	50.46 (3313)	33.38 (4210)
<i>Unknown</i>	4	1	0	1	2
Age					
40-44	22.0 (7045)	33.8 (2415)	20.4 (1179)	19.1 (1255)	17.4 (2196)
45-49	22.7 (7289)	26.4 (1886)	22.4 (1295)	22.0 (1445)	21.1 (2663)
50-54	26.1 (8367)	21.1 (1509)	27.4 (1582)	27.3 (1794)	27.6 (3482)
55-59	29.2 (9385)	18.6 (1330)	29.7 (1713)	31.5 (2071)	33.9 (4271)
Ethnicity					
<i>NZ European[†]</i>	69.46 (22287)	61.3 (4377)	76.39 (4407)	69.23 (4545)	71.03 (8958)
<i>Maori</i>	7.05 (2261)	14.26 (1018)	5.91 (341)	7.75 (509)	3.12 (393)
<i>Pacific Island[*]</i>	3.48 (1116)	8.75 (625)	1.87 (108)	2.83 (186)	1.56 (197)
<i>Asian[#]</i>	5.31 (1703)	5.04 (360)	5.23 (302)	4.90 (322)	5.70 (719)
<i>Others[^]</i>	0.93 (298)	1.44 (103)	0.81 (47)	0.70 (46)	0.81 (102)
<i>Unknown[@]</i>	4421	657	564	957	2243

Table 2: Incidence rate for first prescription of metformin

Groups	Person-time	Number of new cases	Incidence rate cases per person year	Incidence rate cases per 1,000 person- years
Diclofenac	33190	84	0.00253	2.5
TB	30791	85	0.00276	2.8
AAC	35383	150	0.00424	4.2
Statin	70455	391	0.00555	5.5

Table 3: 6 year risk of first prescription of metformin in study groups compared to control group

			Univariable Analysis			Multivariable Analysis ^{1,2}		
	Total	Metformin (%)	HR	95% CI	P	HR	95% CI	P
Cohort								
Diclofenac	7140	84 (1.2)	1.00			1.00		
TB	5769	85 (1.5)	1.25	0.93-1.70	0.142	1.59	1.15-2.20	0.005
AAC	6565	150 (2.3)	1.95	1.50-2.55	<0.0001	2.32	1.74-3.09	<0.0001
Statin	12612	391 (3.1)	2.66	2.10-3.37	<0.0001	3.31	2.56-4.30	<0.0001

¹Cox Regression²Adjusting for: Age, sex, and ethnicity.

Appendices

Appendix 1: Summary of study analysis categories and drug lists

Groups	List of drugs	Sub group
Exclusion criteria	Insulin Neutral, Insulin Isophane, Insulin Isophane with Insulin	
Drugs (associated with increased risk of diabetes or are treatment for diabetes)	Neural, Insulin Lispro with Insulin Lispro Protamine, Insulin Glargine, Insulin Aspart, Insulin Glulisine, Insulin lispro, Acarbose, Glibenclamide, Gliclazide, Glipizide, Pioglitazone, Spironolactone, Cyproterone Acetate with Ethinyloestrodial, Cyproterone acetate, Dexamethasone, Fludrocortisone Acetate, Hydrocortisone tablets, Methylprednisone, Prednisone Sodium Phosphate, Prednisone	
Diclofenac group	Diclofenac Sodium enteric coated tablets, Diclofenac Sodium Long Acting Tablets	
Anti-hypertensives TB Group	Atenolol, Carvedilol, Celiprolol, Labetalol, Metoprolol Succinate, Metoprolol Tartrate, Nadolol, Propanolol, Sotalol, Labetalol	BB
	Bendrofluazide, Chlorthalidone, Indapamide, Chlorothiazide	T
Anti-hypertensives AAC Group	Captopril, Cilazapril, Enalapril, Lisinopril, Quinapril	ACEi
	Candesartan, Losartan	ARB
	Amlodipine, Felodipine, Isradipine, Nifedipine, Diltiazem Hydrochloride, Verapamil Hydrochloride	CC
Statin Group	Atorvastatin, Pravastatin, Simvastatin	
Outcome Group	Metformin Hydrochloride	

Appendix 2: Number of patients persistent with medications in each cohort in every study year

Cohort\Years	2006	2007	2008	2009	2010	2011	%
TB	5769	5202	4834	4547	4339	4115	71.3%
AAC	6565	5958	5583	5227	4955	4654	70.9%
STATIN	12612	11752	11186	10757	10187	9593	76.1%

For peer review only

Appendix 3: 6 year risk of first prescription of metformin in different patient demographics.

					Univariable Analyses			Multivariable Analyses ^{1,2}		
	Total	%	Metformin	%	HR	95% CI	P	HR	95% CI	P
Sex										
M	16999	53.0%	409	1.3%	1.00	-	-	1.00	-	-
F	15083	47.0%	301	0.9%	0.83	0.71-0.96	0.01	0.85	0.72-1.00	0.05
Unknown	4	0.00%	0	0.0%	-	-	-	-	-	-
Age										
40-44	7045	22.0%	163	0.5%	1.00	-	-	1.00	-	-
45-49	7289	22.7%	156	0.5%	0.93	0.74-1.15	0.49	0.87	0.69-1.10	0.25
50-54	8367	26.1%	185	0.6%	0.96	0.77-1.18	0.67	0.88	0.70-1.11	0.27
55-59	9385	29.2%	206	0.6%	0.95	0.77-1.17	0.61	0.96	0.77-1.20	0.71
Ethnicity										
European	22287	69.5%	384	1.2%	1.00	-	-	1.00	-	-
Maori	2261	7.0%	66	0.2%	1.70	1.31-2.21	<0.01	2.23	1.71-2.91	<0.01
PI	1116	3.5%	49	0.2%	2.57	1.91-3.47	<0.01	3.57	2.63-4.85	<0.01
Asian	1703	5.3%	106	0.3%	3.69	2.98-4.57	<0.01	3.72	3.00-4.62	<0.01
Other	298	0.9%	11	0.0%	2.17	1.18-3.93	0.01	2.43	1.33-4.43	<0.01
Note:										
*European = NZ European, Other European, European NFD										
*Pacific Island = Cook Island, Fijian, Niuean, Samoan, Tokelauan, Tongan, Pacific Island, Other Pacific Island										
#Asian = Asian, Chinese, Other Asian, Indian, Southeast Asian										
^Others = African, Latin American/Hispanic, Middle Eastern, other, other ethnicity										

¹Cox Regression²Adjusting for: Age, sex, ethnicity, and study cohorts.

Appendix 4: 743 Patients who swapped study groups during study period

Group Swaps (From/To)	No Metformin	Metformin	Total Patient
Diclofenac Group	207	13	220
Antihypertensives TB Group	78	1	79
Antihypertensives AAC Group	56	1	57
Statin Group	73	11	84
Antihypertensives TB Group	198	8	206
Diclofenac Group	82	1	83
Antihypertensives AAC Group	98	6	104
Study Group	18	1	19
Antihypertensives AAC Group	163	3	166
Diclofenac Group	40	1	41
Antihypertensives TB Group	107	1	108
Statin Group	16	1	17
Statin Group	149	2	151
Diclofenac Group	104	1	105
Antihypertensives TB Group	24	0	24
Antihypertensives AAC Group	21	1	22
Total	717	26	743

Research Protocol

Project title: The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study

Date: April 2012

Principal investigator: Dr. Olivia Currie

Supervisor: Assoc. Professor Derelie Mangin

Project summary:

This is an observational prospective cohort study to assess whether the incidence of new onset diabetes is increased with the use of statin drugs; when compared to blood pressure drugs, and to a control group. The importance is indicated from previous experience with unwanted increased rate of cardiovascular events due to new onset diabetes with use of certain antihypertensives (1, 2). We will look at patients with first prescription of statin drugs and assess the proportion of users who develop diabetes in 6 years. We will compare this with groups of patients with first prescription of drugs for high blood pressure (high diabetes risk control group), and patients with prescription for diclofenac (normal control group). We will use prescription data held electronically in the New Zealand Health Information Service' (NZHIS) Pharmaceutical Collection.

Background:

In modern cardiovascular risk management, statin drugs are popular and beneficial adjuncts for prevention of primary and secondary cardiovascular events. All forms of pharmacotherapy have side effects. Common to statin drugs are increases in liver transaminases, muscle aches, cognition impairment and rhabdomyolysis, albeit rare. However, there is now new evidence to suggest that statin drugs could have drug class effect in causing diabetes in previously non-diabetic individuals (3).

Statin induced diabetes was first observed in the JUPITER trial (4) with relation to rosuvostatin use in non-diabetic subjects. It was reported by physicians involved in the trial as a secondary outcome and concluded that more evidence is needed to confirm the observed effect. Following that, multiple meta-analyses correlated an overall 9% increased risk of diabetes with statin use with newer evidence showing association with pravastatin and rosuvastatin use (5-8). The meta-analyses, should be interpreted with caution as diabetes is often not the primary outcome in the trials analysed. Recent evidence indicates the risk of new onset diabetes with statin use could also be dose dependent (9). These drugs may still have an overall cardiovascular benefit nonetheless (10).

One of the difficulties in assessing the extent of the risk is that patients of higher cardiovascular risk also carry an increased risk of developing diabetes. In order that the risks and benefits of these drugs to be properly considered by patients and doctors, decisions whether to use them, it is very important to understand the extend of this risk in already high risk patients as development of diabetes further increases cardiovascular risk and carries its own morbidity, reducing lifespan and quality of life.

Objective

To assess comparative rates of diabetes development in patients in primary care population started on statin drugs; by comparing them with rates of diabetes development in patients also at high risk of cardiovascular disease started on blood pressure medications but not on statins, and with normal control group.

Methodology:

We will look at patients with first prescription of statin drugs and assess the proportion of users who develop diabetes in the subsequent 6 years. We will compare these rates in patients with first prescription of drugs for high blood pressure (high diabetes risk control group) and patients with prescriptions for diclofenac (normal control group). We will use

1
2
3 electronic prescription data from the New Zealand Health Information Service' (NZHIS)
4 Pharmaceutical Collection.

5
6 Study Design: Prospective cohort study using routinely collected data

7 Study population: New Zealanders between ages 40 and 60, who are commenced on either
8 on statin drugs, or on antihypertensives (high risk control group), or diclofenac (low risk
9 control group) in the year 2005.

10 Exclusion: Patients who previously have diabetes, glucose intolerance, polycystic ovarian
11 syndrome, and those who are already on metformin, thiazides and corticosteroids (all
12 known to increase diabetes risk).

13 Follow up: Cohort will be followed up for 6 years.

14 Outcome measure: First prescription of meformin.

15 Analysis: Proportions compared between statin started, antihypertensives known to have
16 increased diabetes risk (thiazides and beta-blocker), antihypertensives known to have no
17 increased diabetic risk (ACE-inhibitors, ARBs, calcium channel blockers) and diclofenac.

18 **Ethical considerations:**

19 No ethics committee is required by the National Ethics Advisory Committee, New Zealand as
20 stated in the *Ethical Guidelines for Observational Studies: Observational Research, Audits*
21 *and Related Activities, NEAC, December 2006.*

22 Pegasus Health has a method for anonymously electronically extracting and linking these
23 data from the New Zealand Health Information Service' (NZHIS) Pharmaceutical Collection.
24 Data will be de-identified at the point of extraction from the clinical record. Collection of
25 such data will be stored in de-identified manner. This study has been approved for support
26 by the Pegasus Health Research, Audit and Evaluation committee.

27 **References:**

- 28
29
30
31 1. Blackburn D, Wilson T. Antihypertensive medications and blood sugar: theories and implications. *Canadian Journal of*
32 *Cardiology.* 2006;22(3):229-33.
33 2. Aksnes T, Reims H, Kjeldsen S, Mancia G. Antihypertensive Treatment and New Onset Diabetes Mellitus. *Current Hypertension*
34 *Reports.* 2005;7:298-303.
35 3. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes
36 mellitus in postmenopausal women in the Women's Health Initiative. *Archives of internal medicine.* 2012;172(2):144-52. Epub
37 2012/01/11.
38 4. Ridker P, Danielson E, Fonseca F, Genest J, Gotto A, Kastelein J, et al. Rosuvostatin to prevent vascular events in men and
39 women with elevated CRP. *The New England Journal of Medicine.* 2008;359(21):2195-207.
40 5. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular
41 disease: an indirect comparison meta-analysis. *QJM : monthly journal of the Association of Physicians.* 2012;105(2):145-57.
42 Epub 2011/09/17.
43 6. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a
44 network meta-analysis of 170,255 patients from 76 randomized trials. *QJM : monthly journal of the Association of Physicians.*
45 2011;104(2):109-24. Epub 2010/10/12.
46 7. Sattar N, Preiss D, Murray H, Welsh P, Buckley B, de Craen A, et al. Statins and risk of incident diabetes: a collaborative meta-
47 analysis of randomised statin trials. *The Lancet.* 2010;375:735-42.
48 8. Cholesterol Treatment Trialists' collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis
49 of data from 90 056 participants in 14 randomised trials of statins. *Lancet.* 2005;366:1267-78.
50 9. Preiss D, Seshasai S, Welsh P, Murphy S, Ho J, Waters D, et al. Risk of incident diabetes with intensive-dose compared with
51 moderate-dose statin therapy: A Meta-analysis. *JAMA.* 2011;305(4):2556-64.
52 10. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. *Current opinion in lipidology.*
53 2011;22(6):460-6. Epub 2011/09/08.
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Check
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	✓ (refer Manuscript Page 1)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	✓ (refer Manuscript Page 4)
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	✓ (refer Manuscript Page 6)
Objectives	3	State specific objectives, including any prespecified hypotheses	✓ (refer Manuscript Page 6)
Methods			
Study design	4	Present key elements of study design early in the paper	✓ (refer Manuscript Page 7)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	✓ (refer Manuscript Page 7)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	✓ (refer Manuscript Page 7-8)
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	✓ (refer Manuscript Page 8)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	✓ (refer Manuscript Page 7)
Bias	9	Describe any efforts to address potential sources of bias	Not applicable
Study size	10	Explain how the study size was arrived at	✓ (See Figure 1)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	✓ (refer Manuscript Page 8)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	✓ (refer Manuscript Page 8)
			(b) Describe any methods used to examine subgroups and interactions	✓ (refer Manuscript Page 8)
			(c) Explain how missing data were addressed	Not applicable
			(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	✓ (refer Manuscript Page 8)
			(e) Describe any sensitivity analyses	Not applicable
19 20 21 22 23 24 25 26 27	Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	✓ (refer Manuscript Page 9)
			(b) Give reasons for non-participation at each stage	
			(c) Consider use of a flow diagram	✓ (Figure 1, page 17 Manuscript)
28 29 30 31 32 33 34 35 36 37 38 39 40	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	✓ (refer Manuscript Page 9, and table 1, page 19 Manuscript)
			(b) Indicate number of participants with missing data for each variable of interest	✓
			(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	✓ (refer Manuscript Page 9)
41 42 43 44 45 46 47 48	Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	✓ (refer Manuscript Page 9)
			<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
			<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
49 50 51 52 53 54 55 56 57 58	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	✓ (refer Manuscript Page 9, Figure 2 and Table 2)
			(b) Report category boundaries when continuous variables were categorized	
			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
59 60	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and	✓ (refer

		sensitivity analyses	Manuscript Page 10)
Discussion			
Key results	18	Summarise key results with reference to study objectives	✓ (refer Manuscript Page 11)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	✓ (refer Manuscript Page 12)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	✓ (refer Manuscript Page 13)
Generalisability	21	Discuss the generalisability (external validity) of the study results	✓ (refer Manuscript Page 13)
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	✓ (refer Manuscript Page 1)

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.